BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

=>
Uploading 8504.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 00:43:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 582 TO ITERATE

100.0% PROCESSED 582 ITERATIONS 50 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10193 TO 13087
PROJECTED ANSWERS: 576 TO 1424

L2 50 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 00:43:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11751 TO ITERATE

100.0% PROCESSED 11751 ITERATIONS 1078 ANSWERS
SEARCH TIME: 00.00.01

L3 1078 SEA SSS FUL L1

=> file hcaplus, uspatfull

FILE 'HCAPLUS' ENTERED AT 00:44:08 ON 30 SEP 2003

FILE 'USPATFULL' ENTERED AT 00:44:08 ON 30 SEP 2003

=> s l3 and adrenerg?
L4 12 L3 AND ADRENERG?

=> s l4 and (link? or covalent? or conjugat?)
L5 8 L4 AND (LINK? OR COVALENT? OR CONJUGAT?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 8 DUP REM L5 (0 DUPLICATES REMOVED)

=> d l6 abs ibib kwic hitstr 1-8

L6 ANSWER 1 OF 8 USPATFULL on STN
AB The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:243617 USPATFULL
TITLE: Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
INVENTOR(S): Sircar, Jagadish C., San Diego, CA, UNITED STATES
Richards, Mark L., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132808	A1	20020919
APPLICATION INFO.:	US 2002-90044	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275260P	20010312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-**link** immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators,. . .
SUMM [0009] A number of drugs are available for the palliative treatment of

asthma; however, their efficacies vary markedly. Short-acting .beta..sub.2-**adrenergic** agonists, terbutaline and albuterol, long the mainstay of asthma treatment, act primarily during the early phase as bronchodilators. The newer. . .

SUMM [0056] The at least one additional active ingredient may be a short-acting .beta..sub.2-**adrenergic** agonist selected from the group consisting of terbutaline and albuterol; a long-acting .beta..sub.2-**adrenergic** agonist selected from the group consisting of salmeterol and formoterol; an antihistamine selected from the group consisting of loratadine, azelastine. . .

DETD . . . some of the tested cell lines and previous Western blot results with the compounds, there is evidence to suggest a **link** between NF-.kappa.B inhibition and the action of the drugs. Breast cancer cells offer a good model for testing this phenomenon. . .

CLM What is claimed is:

. . . method of claim 6, wherein said at least one additional ingredient is selected from the group consisting of a short-acting .beta..sub.2-**adrenergic** agonist, a long-acting .beta..sub.2-**adrenergic** agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor. . .

14. The method of claim 13, wherein said additional ingredient is selected from the group consisting of a short-acting .beta..sub.2-**adrenergic** agonist, a long-acting .beta..sub.2-**adrenergic** agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor. . .

IT

459807-38-6P	459807-39-7P	459807-40-0P	459807-41-1P	
459807-42-2P	459807-43-3P	459807-44-4P	459807-45-5P	
459807-46-6P	459807-47-7P	459807-48-8P	459807-49-9P	459807-50-2P
459807-51-3P	459807-52-4P	459807-53-5P	459807-54-6P	459807-55-7P
459807-56-8P	459807-57-9P	459807-58-0P	459807-59-1P	459807-60-4P
459807-61-5P	459807-62-6P	459807-63-7P	459807-64-8P	459807-65-9P
459807-66-0P	459807-67-1P	459807-68-2P	459807-69-3P	459807-70-6P
459807-71-7P	459807-72-8P	459807-73-9P	459807-74-0P	459807-75-1P
459807-76-2P	459807-77-3P	459807-78-4P	459807-79-5P	459807-80-8P
459807-81-9P	459807-82-0P	459807-83-1P	459807-84-2P	459807-85-3P
459807-86-4P	459807-87-5P	459807-88-6P	459807-89-7P	459807-90-0P
459807-91-1P	459807-92-2P	459807-93-3P	459807-94-4P	459807-95-5P
459807-96-6P	459807-97-7P	459807-98-8P	459807-99-9P	459808-00-5P
459808-01-6P	459808-02-7P	459808-03-8P	459808-04-9P	459808-05-0P
459808-06-1P	459808-07-2P	459808-08-3P	459808-09-4P	459808-10-7P
459808-11-8P	459808-12-9P	459808-13-0P	459808-14-1P	459808-15-2P
459808-16-3P	459808-17-4P	459808-18-5P	459808-19-6P	459808-20-9P
459808-21-0P	459808-22-1P	459808-23-2P	459808-24-3P	459808-25-4P
459808-26-5P	459808-27-6P	459808-28-7P	459808-29-8P	459808-30-1P
459808-31-2P	459808-32-3P	459808-33-4P	459808-34-5P	459808-35-6P
459808-36-7P	459808-37-8P	459808-38-9P	459808-39-0P	459808-40-3P
459808-41-4P	459808-42-5P	459808-43-6P	459808-44-7P	459808-45-8P
459808-46-9P	459808-47-0P	459808-48-1P	459808-49-2P	459808-50-5P
459808-51-6P	459808-52-7P	459808-53-8P	459808-54-9P	459808-55-0P
459808-56-1P	459808-57-2P	459808-58-3P	459808-59-4P	459808-60-7P
459808-61-8P	459808-62-9P	459808-63-0P	459808-64-1P	459808-65-2P
459808-66-3P	459808-67-4P	459808-68-5P	459808-69-6P	459808-70-9P
459808-71-0P	459808-72-1P	459808-73-2P	459808-74-3P	459808-75-4P
459808-76-5P	459808-77-6P	459808-78-7P	459808-79-8P	459808-80-1P
459808-81-2P	459808-82-3P	459808-83-4P	459808-84-5P	459808-85-6P
459808-86-7P	459808-87-8P	459808-88-9P	459808-89-0P	459808-90-3P

459808-91-4P 459808-92-5P 459808-93-6P 459808-94-7P 459808-95-8P
459808-96-9P 459808-97-0P 459808-98-1P 459808-99-2P 459809-00-8P
459809-01-9P 459809-02-0P 459809-03-1P 459809-04-2P 459809-05-3P
459809-06-4P 459809-07-5P 459809-08-6P 459809-09-7P 459809-10-0P
459809-11-1P 459809-12-2P 459809-13-3P 459809-14-4P 459809-15-5P
459809-16-6P 459809-17-7P 459809-18-8P 459809-19-9P 459809-20-2P
(prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors)

IT **459807-42-2P**
(prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors)

RN 459807-42-2 USPATFULL

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-[(methyltricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]phenyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4747 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172073	B1	20010109
APPLICATION INFO.:	US 1998-49837		19980327 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789
Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DOCUMENT TYPE: Patent

FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lentz, Nelsen L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 5343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-**adrenergic** activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 ethylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-**adrenergic** or .beta.-**adrenergic** activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

55581-45-8P	73889-11-9P	180156-51-8P	180156-53-0P	180156-54-1P
180156-56-3P	180156-58-5P	180156-60-9P	180156-61-0P	180156-63-2P
180156-65-4P	180156-67-6P	180156-69-8P	180156-71-2P	180156-73-4P
180156-75-6P	180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P
180156-85-8P	180156-87-0P	180156-89-2P	180156-91-6P	180156-92-7P
180156-94-9P	180156-96-1P	180156-98-3P	180157-00-0P	180157-02-2P
180157-04-4P	180157-06-6P	180157-08-8P	180157-10-2P	180157-12-4P
180157-14-6P	180157-16-8P	180157-18-0P	180157-20-4P	180157-22-6P
180157-24-8P	180157-26-0P	180157-28-2P	180157-30-6P	180157-32-8P
180157-34-0P	180157-36-2P	180157-38-4P	180157-40-8P	180157-42-0P
180157-44-2P	180157-46-4P	180157-48-6P	180157-50-0P	180157-52-2P
180157-54-4P	180157-56-6P	180157-58-8P	180157-60-2P	180157-62-4P
180157-64-6P	180157-66-8P	180157-68-0P	180157-70-4P	180157-72-6P
180157-74-8P	180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P
180157-84-0P	180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P
180157-94-2P	180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P
180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
180158-49-0P	180158-50-3P	180158-51-4P	**180158-52-5P**	
180158-53-6P	180158-54-7P	180158-55-8P	180158-57-0P	180158-58-1P
180158-59-2P	180158-60-5P	180158-61-6P	180158-63-8P	180158-65-0P
180158-67-2P	180158-69-4P	180158-71-8P	180158-73-0P	180158-75-2P

180158-77-4P 180158-79-6P 180158-81-0P 180158-83-2P 180158-85-4P
180158-87-6P 180158-89-8P 180158-90-1P 180158-91-2P 180158-92-3P
180158-93-4P 180158-94-5P 180158-95-6P 180158-96-7P 180158-97-8P
180158-98-9P 180158-99-0P 180159-00-6P 180159-01-7P 180159-03-9P
180159-05-1P 180159-07-3P 180159-09-5P 180159-11-9P 180159-12-0P
180159-13-1P 180159-14-2P 180159-15-3P 180159-16-4P 180159-17-5P
180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P 180159-22-2P
180159-23-3P 180159-24-4P 180159-25-5P 180159-26-6P 180159-27-7P
180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P 180159-35-7P
180159-37-9P 180159-39-1P 180159-41-5P 180159-43-7P 180159-45-9P
180159-47-1P 180159-49-3P 180159-51-7P 180159-53-9P 180159-55-1P
180159-57-3P 180159-59-5P 180159-61-9P 180159-63-1P 180159-65-3P
180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P
180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P
180159-87-9P 180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P
180159-95-9P 180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P
180160-00-3P 180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P
180160-05-8P 180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P
180160-10-5P 180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P
180160-15-0P 180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P
180160-20-7P 180160-21-8P 180160-22-9P 180160-23-0P 180160-24-1P
180160-25-2P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

IT 180160-26-3P 180160-27-4P 180160-28-5P 180160-29-6P 180160-30-9P
180160-31-0P 180160-32-1P **180160-33-2P** 180160-34-3P
180160-35-4P 180160-36-5P 180271-36-7P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

IT **180158-52-5P 180160-33-2P**
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

RN 180158-52-5 USPATFULL
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 180160-33-2 USPATFULL
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 8 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -**adrenergic** receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:41028 USPATFULL
TITLE: Method of synergistic treatment for benign prostatic hyperplasia
INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
Stoner, Elizabeth, Westfield, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046183		20000404
APPLICATION INFO.:	US 1998-27105		19980220 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-428595, filed on 25 Apr 1995, now patented, Pat. No. US 5753641 which is a continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 20 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Fitch, Catherine D.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 5342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -**adrenergic** receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as. . .

SUMM . . . prostatic hyperplasia (BPH), involving combination therapy of administering therapeutically effective amounts of a 5.alpha.-reductase inhibitor in combination with an .alpha..sub.1 -**adrenergic** receptor blocker.

SUMM . . . thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly an .alpha..sub.1 -**adrenergic** receptor blocking agent, also termed herein ".alpha..sub.1 -blocker".

SUMM Thus, the combined effect of a 5.alpha.-reductase inhibitor in inhibiting DHT production in the prostate and the .alpha..sub.1 -**adrenergic** receptor blocker, i.e. terazosin, will result in a greater effect on suppressing the growth and symptomatic relief of enlarged prostate. . .

SUMM Alpha.sub.1 -**adrenergic** receptor blockers function generally as anti-hypertensive agents by blocking .alpha.-**adrenergic** receptor sites. They relax stromal (smooth) tissue in the bladder, which cause fibrous tissue to contract when stimulated by noradrenaline. . .

SUMM .alpha.-**Adrenergic** blocking agents bind selectively to the .alpha. class of **adrenergic** receptors and thereby interfere with the capacity of sympathomimetic amines to initiate actions at these sites.

SUMM There are prominent differences in the relative abilities of .alpha.-**adrenergic** blocking agents to antagonize the effects of sympathomemetic amines at the two subtypes of a receptors. It is known that. . . selective .alpha..sub.1 -blocking agent, while phentolamine is only three to five times more potent in inhibiting .alpha..sub.1 -than .alpha..sub.2 -**adrenergic** receptors. In contrast, yohimbine is a selective .alpha..sub.2 -blocker and has been shown to prevent the antihypertensive effects of clonidine,. . .

SUMM However, preferred in this invention are .alpha.-**adrenergic** blockers which preferably be .alpha..sub.1 -blockers and have little or no .alpha..sub.2 -blocking activity.

SUMM Examples of .alpha.-**adrenergic** receptor blockers are terazosin (Abbott-Hytrin*) whose chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine, as described in German Patent 2,646, 186 and U.S. Pat.. . .

SUMM . . . invention, prepared in accordance with the method described above, are, as already described, potent agents in combination with an alpha-one **adrenergic** receptor blocker for the treatment of BPH.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are **linked** together are cyclopentane, cyclohexane or a benzene ring; and

SUMM . . . with the methods described above, are, as already described, can be used to treat BPH in combination with an alpha **adrenergic** blocker by oral, parenteral or topical administration.

SUMM In this invention, the a.sub.1 -**adrenergic** receptor blocker, and the 5a-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral. . .

IT 98319-25-6P 98319-28-9P 98319-29-0P 103335-45-1P 103335-46-2P

103335-48-4P 103335-56-4P 103335-57-5P 103497-68-3P 119169-78-7P
119347-91-0P 119347-96-5P 119348-05-9P 133216-44-1P 134067-56-4P
134067-64-4P 134217-16-6P 134217-17-7P 138715-91-0P 139229-87-1P
139229-88-2P 139229-89-3P 139229-90-6P 139229-91-7P 139229-92-8P
139229-93-9P 139229-94-0P 139229-95-1P 139229-97-3P 139230-03-8P
139230-04-9P 139255-63-3P 139344-08-4P 139344-09-5P 139512-72-4P
139512-73-5P 139512-75-7P 139512-76-8P 139512-77-9P 139512-78-0P
139512-79-1P 139512-80-4P 139523-47-0P 139539-84-7P 139755-31-0P
144879-06-1P 144879-08-3P 144879-10-7P 144879-16-3P 144879-17-4P
144879-18-5P 144879-21-0P 144879-25-4P 144879-27-6P 144879-29-8P
144879-32-3P 144879-33-4P 144879-34-5P 144879-35-6P 144879-36-7P
144879-37-8P 144879-38-9P 144879-39-0P 144879-40-3P 144879-41-4P
144879-48-1P 144879-50-5P 144879-55-0P 144879-60-7P 145191-61-3P
146032-67-9P 146032-69-1P 146057-96-7P 146142-97-4P
146143-98-8P
(prepn. of)

IT **146032-67-9P**
(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 8 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -**adrenergic** receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:54885 USPATFULL
TITLE:	Method of treatment for benign prostatic hyperplasia
INVENTOR(S):	Gormley, Glenn J., Westfield, NJ, United States Stoner, Elizabeth, Westfield, NJ, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5753641		19980519
APPLICATION INFO.:	US 1995-428595		19950425 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 10 Mar 1991, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Criares, Theodore J.
LEGAL REPRESENTATIVE:	Fitch, Catherine D., Nicholson, William H.
NUMBER OF CLAIMS:	2
EXEMPLARY CLAIM:	1
LINE COUNT:	5371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -**adrenergic** receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as. . .

SUMM . . . prostatic hyperplasia (BPH), involving combination therapy of administering therapeutically effective amounts of a 5.alpha.-reductase inhibitor in combination with an .alpha..sub.1 -**adrenergic** receptor blocker.

SUMM . . . thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly an .alpha..sub.1 -**adrenergic** receptor blocking agent, also termed herein ".alpha..sub.1 -blocker".

SUMM Thus, the combined effect of a 5.alpha.-reductase inhibitor in inhibiting DHT production in the prostate and the .alpha..sub.1 -**adrenergic** receptor blocker, i.e. terazosin, will result in a greater effect on suppressing the growth and symptomatic relief of enlarged prostate. . .

SUMM Alpha.sub.1 -**adrenergic** receptor blockers function generally as anti-hypertensive agents by blocking .alpha.-**adrenergic** receptor sites. They relax stromal (smooth) tissue in the bladder, which cause fibrous tissue to contract when stimulated by noradrenaline. . .

SUMM .alpha.-**Adrenergic** blocking agents bind selectively to the .alpha. class of **adrenergic** receptors and thereby interfere with the capacity of sympathomimetic amines to initiate actions at these sites.

SUMM There are prominent differences in the relative abilities of .alpha.-**adrenergic** blocking agents to antagonize the effects of sympathomemetic amines at the two subtypes of .alpha. receptors. It is known that. . . selective .alpha..sub.1 -blocking agent, while

phentolamine is only three to five times more potent in inhibiting .alpha..sub.1 - than .alpha..sub.2 -**adrenergic** receptors. In contrast, yohimbine is a selective .alpha..sub.2 -blocker and has been shown to prevent the antihypertensive effects of clonidine,. . .

SUMM However, preferred in this invention are .alpha.-**adrenergic** blockers which preferably be .alpha..sub.1 -blockers and have little or no .alpha..sub.2 -blocking activity.

SUMM Examples of .alpha.-**adrenergic** receptor blockers are terazosin (Abbott-Hytrin*) whose chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazo-linyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine, as described in German Patent 2,646,186 and U.S. Pat. No.. . .

SUMM . . . invention, prepared in accordance with the method described above, are, as already described, potent agents in combination with an alpha-one **adrenergic** receptor blocker for the treatment of BPH.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are **linked** together are cyclopentane, cyclohexane or a benzene ring; and

SUMM . . . with the methods described above, are, as already described, can be used to treat BPH in combination with an alpha **adrenergic** blocker by oral, parenteral or topical administration.

SUMM In this invention, the .alpha..sub.1 -**adrenergic** receptor blocker, and the 5a-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral. . .

IT 98319-25-6P 98319-28-9P 98319-29-0P 103335-45-1P 103335-46-2P
103335-48-4P 103335-56-4P 103335-57-5P 103497-68-3P 119169-78-7P
119347-91-0P 119347-96-5P 119348-05-9P 133216-44-1P 134067-56-4P
134067-64-4P 134217-16-6P 134217-17-7P 138715-91-0P 139229-87-1P
139229-88-2P 139229-89-3P 139229-90-6P 139229-91-7P 139229-92-8P
139229-93-9P 139229-94-0P 139229-95-1P 139229-97-3P 139230-03-8P
139230-04-9P 139255-63-3P 139344-08-4P 139344-09-5P 139512-72-4P
139512-73-5P 139512-75-7P 139512-76-8P 139512-77-9P 139512-78-0P
139512-79-1P 139512-80-4P 139523-47-0P 139539-84-7P 139755-31-0P
144879-06-1P 144879-08-3P 144879-10-7P 144879-16-3P 144879-17-4P
144879-18-5P 144879-21-0P 144879-25-4P 144879-27-6P 144879-29-8P
144879-32-3P 144879-33-4P 144879-34-5P 144879-35-6P 144879-36-7P
144879-37-8P 144879-38-9P 144879-39-0P 144879-40-3P 144879-41-4P
144879-48-1P 144879-50-5P 144879-55-0P 144879-60-7P 145191-61-3P
146032-67-9P 146032-69-1P 146057-96-7P 146142-97-4P
146143-98-8P
(prepn. of)

IT **146032-67-9P**
(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:42357 USPATFULL
TITLE:	Compounds having effects on serotonin-related systems
INVENTOR(S):	Hibschman, David J., Bargersville, IN, United States Krushinski, Jr., Joseph H., Indianapolis, IN, United States Rasmussen, Kurt, Fishers, IN, United States Rocco, Vincent P., Indianapolis, IN, United States Schaus, John M., Zionsville, IN, United States Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741789		19980421
APPLICATION INFO.:	US 1995-467434		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Palmberg, Arleen, Boone, David E.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5902		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-**adrenergic** activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-**adrenergic** or .beta.-**adrenergic** activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
180158-49-0P	180158-50-3P	180158-51-4P	**180158-52-5P**	
180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P
180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P

180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P 180160-00-3P
180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P 180160-05-8P
180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P 180160-10-5P
180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P 180160-15-0P
180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P 180160-20-7P
180160-21-8P 180271-36-7P 185255-45-2P 185255-47-4P 185255-49-6P
185255-51-0P 185255-53-2P 185255-55-4P 185255-67-8P 185255-71-4P
185255-73-6P 190785-69-4P 190786-32-4P 190786-36-8P 190788-23-9P
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

IT **180158-52-5P**
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L6 ANSWER 6 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:38539 USPATFULL

TITLE: Compounds having effects on serotonin-related systems

INVENTOR(S): Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627196		19970506
APPLICATION INFO.:	US 1995-468948		19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Bottino, Anthony
LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
LINE COUNT: 5947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-**adrenergic** activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-**adrenergic** or .beta.-**adrenergic** activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P

180158-12-7P 180158-13-8P 180158-15-0P 180158-17-2P 180158-19-4P
180158-20-7P 180158-22-9P 180158-24-1P 180158-26-3P 180158-28-5P
180158-30-9P 180158-32-1P 180158-34-3P 180158-36-5P 180158-38-7P
180158-39-8P 180158-40-1P 180158-41-2P 180158-42-3P 180158-43-4P
180158-44-5P 180158-45-6P 180158-46-7P 180158-47-8P 180158-48-9P
180158-49-0P 180158-50-3P 180158-51-4P **180158-52-5P**
180158-53-6P 180158-55-8P 180158-57-0P 180158-58-1P 180158-59-2P
180158-61-6P 180158-63-8P 180158-65-0P 180158-67-2P 180158-69-4P
180158-71-8P 180158-73-0P 180158-75-2P 180158-77-4P 180158-79-6P
180158-81-0P 180158-83-2P 180158-85-4P 180158-87-6P 180158-89-8P
180158-91-2P 180158-93-4P 180158-94-5P 180158-96-7P 180158-97-8P
180158-98-9P 180159-00-6P 180159-01-7P 180159-03-9P 180159-07-3P
180159-09-5P 180159-12-0P 180159-14-2P 180159-15-3P 180159-16-4P
180159-17-5P 180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P
180159-22-2P 180159-23-3P 180159-25-5P 180159-26-6P 180159-27-7P
180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P 180159-37-9P
180159-39-1P 180159-41-5P 180159-43-7P 180159-45-9P 180159-47-1P
180159-49-3P 180159-50-6P 180159-51-7P 180159-53-9P 180159-55-1P
180159-57-3P 180159-59-5P 180159-63-1P 180159-65-3P 180159-67-5P
180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P 180159-77-7P
180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P 180159-87-9P
180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P 180159-95-9P
180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P 180160-00-3P
180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P 180160-05-8P
180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P 180160-10-5P
180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P 180160-15-0P
180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P 180160-20-7P
180160-21-8P 180271-36-7P 185255-45-2P 185255-47-4P 185255-49-6P
185255-51-0P 185255-53-2P 185255-55-4P 185255-67-8P 185255-71-4P
185255-73-6P 190785-69-4P 190786-32-4P 190786-36-8P 190788-23-9P
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

IT **180158-52-5P**
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



O HCl

L6 ANSWER 7 OF 8 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:106493 USPATFULL
TITLE: Compounds having effects on serotonin-related systems
INVENTOR(S): Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576321		19961119
APPLICATION INFO.:	US 1995-468900		19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Bottino, Anthony
LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 5725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . antidepressant drugs are now known to be active as inhibitors of serotonin reuptake, and also to have anticholinergic, antihistaminic or anti-.alpha.-**adrenergic** activity. More recently, it has become possible to study the function of drugs at individual receptors in vitro or ex. . .

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Many other serotonin 1.sub.A receptor antagonists typically have .alpha.-**adrenergic** or .beta.-**adrenergic** activity as well, and are therefore nonselective for 5HT-1.sub.A activity.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering,

cleansing and the like, beyond any. . .

IT 55581-45-8P 73889-11-9P 180156-51-8P 180156-54-1P 180156-56-3P
180156-60-9P 180156-61-0P 180156-63-2P 180156-67-6P 180156-69-8P
180156-73-4P 180156-75-6P 180156-77-8P 180156-79-0P 180156-81-4P
180156-83-6P 180156-85-8P 180156-87-0P 180156-89-2P 180156-91-6P
180156-92-7P 180156-94-9P 180156-96-1P 180156-98-3P 180157-00-0P
180157-02-2P 180157-04-4P 180157-06-6P 180157-08-8P 180157-10-2P
180157-12-4P 180157-14-6P 180157-16-8P 180157-18-0P 180157-20-4P
180157-22-6P 180157-24-8P 180157-26-0P 180157-28-2P 180157-30-6P
180157-34-0P 180157-36-2P 180157-38-4P 180157-40-8P 180157-42-0P
180157-44-2P 180157-46-4P 180157-50-0P 180157-52-2P 180157-54-4P
180157-56-6P 180157-58-8P 180157-60-2P 180157-62-4P 180157-64-6P
180157-66-8P 180157-68-0P 180157-70-4P 180157-72-6P 180157-74-8P
180157-76-0P 180157-78-2P 180157-80-6P 180157-82-8P 180157-84-0P
180157-86-2P 180157-88-4P 180157-90-8P 180157-92-0P 180157-94-2P
180157-95-3P 180157-96-4P 180157-98-6P 180158-00-3P 180158-02-5P
180158-04-7P 180158-06-9P 180158-08-1P 180158-10-5P 180158-12-7P
180158-15-0P 180158-17-2P 180158-19-4P 180158-22-9P 180158-24-1P
180158-26-3P 180158-28-5P 180158-30-9P 180158-32-1P 180158-34-3P
180158-36-5P 180158-38-7P 180158-39-8P 180158-40-1P 180158-41-2P
180158-42-3P 180158-43-4P 180158-44-5P 180158-45-6P 180158-46-7P
180158-47-8P 180158-48-9P 180158-49-0P 180158-50-3P 180158-51-4P
180158-52-5P 180158-53-6P 180158-54-7P 180158-55-8P
180158-57-0P 180158-58-1P 180158-59-2P 180158-60-5P 180158-61-6P
180158-65-0P 180158-67-2P 180158-69-4P 180158-71-8P 180158-73-0P
180158-75-2P 180158-77-4P 180158-79-6P 180158-81-0P 180158-83-2P
180158-85-4P 180158-87-6P 180158-89-8P 180158-90-1P 180158-91-2P
180158-92-3P 180158-93-4P 180158-94-5P 180158-97-8P 180158-98-9P
180159-01-7P 180159-03-9P 180159-07-3P 180159-09-5P 180159-11-9P
180159-12-0P 180159-13-1P 180159-14-2P 180159-15-3P 180159-16-4P
180159-17-5P 180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P
180159-22-2P 180159-23-3P 180159-24-4P 180159-25-5P 180159-26-6P
180159-27-7P 180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P
180159-34-6P 180159-35-7P 180159-37-9P 180159-39-1P 180159-41-5P
180159-43-7P 180159-45-9P 180159-47-1P 180159-49-3P 180159-51-7P
180159-53-9P 180159-55-1P 180159-57-3P 180159-59-5P 180159-63-1P
180159-65-3P 180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P
180159-75-5P 180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P
180159-84-6P 180159-85-7P 180159-87-9P 180159-89-1P 180159-91-5P
180159-93-7P 180159-94-8P 180159-95-9P 180159-96-0P 180159-97-1P
180159-98-2P 180159-99-3P 180160-00-3P 180160-01-4P 180160-02-5P
180160-03-6P 180160-04-7P 180160-05-8P 180160-06-9P 180160-07-0P
180160-08-1P 180160-09-2P 180160-10-5P 180160-11-6P 180160-12-7P
180160-13-8P 180160-14-9P 180160-15-0P 180160-16-1P 180160-17-2P
180160-18-3P 180160-19-4P 180160-20-7P 180160-22-9P 180160-23-0P
180160-24-1P 180160-25-2P 180160-26-3P 180160-27-4P 180160-28-5P
180160-29-6P 180160-30-9P 180160-31-0P 180160-32-1P
180160-33-2P 180160-34-3P 180160-35-4P 180160-36-5P
180271-36-7P 185255-45-2P
(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

IT **180158-52-5P 180160-33-2P**
(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 180160-33-2 USPATFULL
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 8 USPATFULL on STN
AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.A is ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:91061 USPATFULL
TITLE:	Carbostyril oxytocin receptor antagonists
INVENTOR(S):	Freidinger, Roger M., Lansdale, PA, United States Pawluczyk, Joseph M., Warminster, PA, United States Pettibone, Douglas J., Shalfont, PA, United States Williams, Peter D., Harleysville, PA, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5356904		19941018	
APPLICATION INFO.:	US 1992-957491		19921007	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Cintins, Marianne M.			

ASSISTANT EXAMINER: Travers, Russell
LEGAL REPRESENTATIVE: Appollina, Mary A., DiPrima, Joseph F.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 7213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Tocolytic (uterine-relaxing) agents that are currently in use include .beta..sub.2 -**adrenergic** agonists, magnesium sulfate and calsium antagonists. Ritodrine, the leading .beta..sub.2 -**adrenergic** agonists, causes a number of cardiovascular and metabolic side effects in the mother, including tachycardia, increased renin secretion, hyperglycemia (and reactive hypoglycemia in the infant) and pulmonary edema. Other .beta..sub.2 -**adrenergic** agonists, including terbutaline and albuterol have side effects similar to those of ritodrine. Magnesium sulfate at plasma concentrations above the. . .

DETD . . . achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrlates and cross-**linked** or amphipathic block copolymers of hydrogels.

IT 131582-88-2P 131582-89-3P 131582-90-6P 131582-91-7P 131582-97-3P
131582-99-5P 131583-01-2P 131583-04-5P 131583-05-6P 131583-06-7P
131583-07-8P **131583-08-9P** 131583-09-0P 131583-10-3P
131583-11-4P 131583-13-6P 131583-14-7P 131583-15-8P 131583-17-0P
131583-18-1P 131583-19-2P 131583-20-5P 131583-21-6P 131583-23-8P
131583-24-9P 131583-26-1P 131583-27-2P 131583-28-3P 131583-29-4P
131583-30-7P 131583-31-8P 131583-33-0P 131583-34-1P 131583-35-2P
131583-36-3P 131583-37-4P 131583-38-5P 131583-39-6P 131583-40-9P
131583-41-0P 131583-42-1P 131583-43-2P 131583-44-3P 131583-45-4P
131583-46-5P 131583-49-8P 131583-50-1P 131583-51-2P 131583-52-3P
131583-53-4P 131583-57-8P 131583-58-9P 131583-60-3P 131583-61-4P
131583-63-6P 131583-64-7P 131583-65-8P 131583-66-9P 131583-67-0P
131583-71-6P 131583-72-7P 131583-74-9P 131583-75-0P 131583-76-1P
131583-77-2P 131583-79-4P 131583-81-8P 131583-83-0P 131583-84-1P
131583-87-4P 131583-88-5P 131583-89-6P 131583-90-9P 131583-91-0P
131583-92-1P 131583-93-2P 131583-95-4P 131583-96-5P 131583-97-6P
131583-98-7P 131583-99-8P 131584-01-5P 131584-02-6P 131584-03-7P
131584-04-8P 131584-05-9P 131584-07-1P 131584-09-3P 131584-11-7P
131584-12-8P 131584-13-9P 131584-14-0P 131584-15-1P 131584-16-2P
131584-17-3P 131584-18-4P 131584-19-5P 131584-20-8P 131584-21-9P
131584-22-0P 131584-23-1P 131584-24-2P 131584-25-3P 131584-26-4P
131584-27-5P 131584-28-6P 131584-29-7P 131584-30-0P 131584-33-3P
131584-36-6P 131584-37-7P 131584-38-8P 131584-40-2P 131584-41-3P
131584-42-4P 131584-43-5P 131584-44-6P 131584-45-7P 131584-46-8P
131584-47-9P 131584-48-0P 131584-49-1P 131584-50-4P 131584-51-5P
131584-52-6P 131584-53-7P 131584-54-8P 131584-55-9P 131584-56-0P
131584-57-1P 131584-58-2P 131584-59-3P 131584-60-6P 131584-61-7P
131584-62-8P 131584-63-9P 131584-64-0P 131584-65-1P 131584-66-2P
131584-67-3P 131584-68-4P 131584-69-5P 131584-70-8P 131584-71-9P
131584-73-1P 131584-74-2P 131584-76-4P 131584-77-5P 131584-78-6P
131584-79-7P 131584-80-0P 131584-81-1P 131584-82-2P 131584-83-3P
131584-85-5P 131584-87-7P 131584-88-8P 131584-89-9P 131584-90-2P
131584-92-4P 131584-93-5P 131584-94-6P 131584-95-7P 131584-98-0P
131584-99-1P 131585-00-7P 131585-01-8P 131585-02-9P 131585-03-0P
131585-04-1P 131585-05-2P 131585-06-3P 131585-07-4P 131585-08-5P
131585-09-6P 131585-10-9P 131585-11-0P 131585-12-1P 131585-13-2P
131585-14-3P 131585-15-4P 131585-16-5P 131585-17-6P 131585-18-7P
131585-19-8P 131585-22-3P 131585-23-4P 131585-24-5P 131585-25-6P

131585-26-7P 131585-27-8P 131585-28-9P 131585-29-0P 131585-30-3P
131585-31-4P 131585-32-5P 131585-33-6P 131585-34-7P 131585-35-8P
131585-36-9P 131585-37-0P 131585-39-2P 131585-42-7P 131585-47-2P
131585-48-3P 131585-49-4P 131585-50-7P 131585-51-8P 131585-52-9P
131585-53-0P 131585-54-1P 131585-55-2P 131585-56-3P 131585-57-4P
131585-58-5P 131585-59-6P 131585-60-9P 131585-61-0P 131585-62-1P
131585-63-2P 131585-64-3P 131585-65-4P 131585-66-5P 131585-67-6P
131585-68-7P 131585-69-8P 131585-70-1P 131585-71-2P 131585-72-3P
131585-73-4P 131585-74-5P 131585-75-6P 131585-76-7P 131585-77-8P
131585-78-9P 131585-79-0P 131585-80-3P 131585-81-4P 131585-82-5P
(carbostyril oxytocin receptor antagonists)

IT **131583-08-9P**
(carbostyril oxytocin receptor antagonists)

RN 131583-08-9 USPATFULL

CN Benzamide, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



=> file stnguide

```
     (FILE 'HOME' ENTERED AT 00:43:06 ON 30 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 00:43:28 ON 30 SEP 2003
L1             STRUCTURE UPLOADED
L2              50 S L1 SSS SAM
L3            1078 S L1 SSS FULL

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 00:44:08 ON 30 SEP 2003
L4              12 S L3 AND ADRENERG?
L5               8 S L4 AND (LINK? OR COVALENT? OR CONJUGAT?)
L6               8 DUP REM L5 (0 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 00:47:19 ON 30 SEP 2003

     FILE 'STNGUIDE' ENTERED AT 01:05:00 ON 30 SEP 2003

     FILE 'REGISTRY' ENTERED AT 01:05:09 ON 30 SEP 2003
L7             STRUCTURE UPLOADED
L8               0 S L7 SSS SAM
L9               0 S L7 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 01:06:48 ON 30 SEP 2003

     FILE 'REGISTRY' ENTERED AT 01:10:52 ON 30 SEP 2003
L10            STRUCTURE UPLOADED
L11             50 S L10 SSS SAM
L12           1099 S L10 SSS FULL

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 01:11:40 ON 30 SEP 2003
L13              8 S L12 AND (LINK? OR COVALENT? OR CONJUGAT?) AND ADRENERG?
L14              8 DUP REM L13 (0 DUPLICATES REMOVED)
L15             28 S L12 AND (LINK? OR COVALENT? OR CONJUGAT?)
L16             27 DUP REM L15 (1 DUPLICATE REMOVED)
L17              0 S L14 NOT L6
L18              8 S L16 AND ADRENERG?

     FILE 'STNGUIDE' ENTERED AT 01:14:45 ON 30 SEP 2003
```

=> d l16 abs ibib kwic hitstr 1-27

L16 ANSWER 1 OF 27 USPATFULL on STN

AB The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:243617 USPATFULL
TITLE: Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
INVENTOR(S): Sircar, Jagadish C., San Diego, CA, UNITED STATES
Richards, Mark L., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002132808	A1	20020919	
APPLICATION INFO.:	US 2002-90044	A1	20020227	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-275260P	20010312	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-**link** immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators,. . .

DETD . . . some of the tested cell lines and previous Western blot results with the compounds, there is evidence to suggest a **link** between NF-.kappa.B inhibition and the action of the drugs. Breast cancer cells offer a good model for testing this phenomenon. . .

IT

459807-38-6P	459807-39-7P	459807-40-0P	459807-41-1P	
459807-42-2P	459807-43-3P	459807-44-4P	459807-45-5P	
459807-46-6P	459807-47-7P	459807-48-8P	459807-49-9P	459807-50-2P
459807-51-3P	459807-52-4P	459807-53-5P	459807-54-6P	459807-55-7P
459807-56-8P	459807-57-9P	459807-58-0P	459807-59-1P	459807-60-4P
459807-61-5P	459807-62-6P	459807-63-7P	459807-64-8P	459807-65-9P
459807-66-0P	459807-67-1P	459807-68-2P	459807-69-3P	459807-70-6P
459807-71-7P	459807-72-8P	459807-73-9P	459807-74-0P	459807-75-1P
459807-76-2P	459807-77-3P	459807-78-4P	459807-79-5P	459807-80-8P
459807-81-9P	459807-82-0P	459807-83-1P	459807-84-2P	459807-85-3P
459807-86-4P	459807-87-5P	459807-88-6P	459807-89-7P	459807-90-0P
459807-91-1P	459807-92-2P	459807-93-3P	459807-94-4P	459807-95-5P
459807-96-6P	459807-97-7P	459807-98-8P	459807-99-9P	459808-00-5P
459808-01-6P	459808-02-7P	459808-03-8P	459808-04-9P	459808-05-0P
459808-06-1P	459808-07-2P	459808-08-3P	459808-09-4P	459808-10-7P

459808-11-8P 459808-12-9P 459808-13-0P 459808-14-1P 459808-15-2P
459808-16-3P 459808-17-4P 459808-18-5P 459808-19-6P 459808-20-9P
459808-21-0P 459808-22-1P 459808-23-2P 459808-24-3P 459808-25-4P
459808-26-5P 459808-27-6P 459808-28-7P 459808-29-8P 459808-30-1P
459808-31-2P 459808-32-3P 459808-33-4P 459808-34-5P 459808-35-6P
459808-36-7P 459808-37-8P 459808-38-9P 459808-39-0P 459808-40-3P
459808-41-4P 459808-42-5P 459808-43-6P 459808-44-7P 459808-45-8P
459808-46-9P 459808-47-0P 459808-48-1P 459808-49-2P 459808-50-5P
459808-51-6P 459808-52-7P 459808-53-8P 459808-54-9P 459808-55-0P
459808-56-1P 459808-57-2P 459808-58-3P 459808-59-4P 459808-60-7P
459808-61-8P 459808-62-9P 459808-63-0P 459808-64-1P 459808-65-2P
459808-66-3P 459808-67-4P 459808-68-5P 459808-69-6P 459808-70-9P
459808-71-0P 459808-72-1P 459808-73-2P 459808-74-3P 459808-75-4P
459808-76-5P 459808-77-6P 459808-78-7P 459808-79-8P 459808-80-1P
459808-81-2P 459808-82-3P 459808-83-4P 459808-84-5P 459808-85-6P
459808-86-7P 459808-87-8P 459808-88-9P 459808-89-0P 459808-90-3P
459808-91-4P 459808-92-5P 459808-93-6P 459808-94-7P 459808-95-8P
459808-96-9P 459808-97-0P 459808-98-1P 459808-99-2P 459809-00-8P
459809-01-9P 459809-02-0P 459809-03-1P 459809-04-2P 459809-05-3P
459809-06-4P 459809-07-5P 459809-08-6P 459809-09-7P 459809-10-0P
459809-11-1P 459809-12-2P 459809-13-3P 459809-14-4P 459809-15-5P
459809-16-6P 459809-17-7P 459809-18-8P 459809-19-9P 459809-20-2P
(prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors)

IT **459807-42-2P**
(prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors)

RN 459807-42-2 USPATFULL

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[4-[(methyltricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]phenyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB N,N-Dimethyl-1-adamantamine-HF (2MAAHF) is a cryst. mol. species with a three-center **covalent** N-H-F bond; it can be recovered unchanged from aq. soln. The satd. soln. is a liq. pentahydrate; this quantity of H2O is insufficient to form a clathrate cage around 2MAAHF. Incremental increase of H2O content results in dramatic changes in the NMR spectrum of 2MAAHF. This behavior differs from that obsd. with the ionic salt 2MAAH+Cl-. The satd. soln. of 2MAAH+Cl- contains 11.5 mol equiv. H2O, the amt. required for formation of a clathrate cage about such cations, and essentially no change in the NMR spectrum takes place on diln. Even in dil. solns., the spectra of 2MAAHF and 2MAAH+Cl- are not the same. The NMR spectral properties of 2MAAHF cannot be explained by effect of either F- or 2MAAH+ alone, but must result from the combined effects of both. This leads us to assume that 2MAAHF remains as an unionized mol. species in aq. soln.

ACCESSION NUMBER: 2002:98131 HCAPLUS
DOCUMENT NUMBER: 137:62990
TITLE: Hydrogen bonding. Part 79. FT-NMR study of hydration

of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride

AUTHOR(S): Benning, Nicole M.; Harmon, Kenneth M.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309, USA

SOURCE: Journal of Molecular Structure (2002), 606(1-3), 197-203
CODEN: JMOSB4; ISSN: 0022-2860
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N,N-Dimethyl-1-adamantamine-HF (2MAAHF) is a cryst. mol. species with a three-center **covalent** N-H-F bond; it can be recovered unchanged from aq. soln. The satd. soln. is a liq. pentahydrate; this quantity of. . .

IT Bond
(**covalent**, three center N-H-F; hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

IT **439610-54-5**
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

IT **439610-50-1 439610-51-2 439610-52-3**
RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); FORM (Formation, nonpreparative); PROC (Process)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

IT **3727-95-5** 7732-18-5, Water, properties **273720-80-2**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

IT **3717-40-6 439610-53-4**
RL: PRP (Properties)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

IT **439610-54-5**
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

RN 439610-54-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, monohydrate (9CI) (CA INDEX NAME)



● HF

● H_2O

IT **439610-50-1 439610-51-2 439610-52-3**
RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); FORM (Formation, nonpreparative); PROC (Process)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)

RN 439610-50-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride, hydrate (2:23) (9CI) (CA INDEX NAME)



● HCl

23/2 H_2O

RN 439610-51-2 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, pentahydrate (9CI) (CA INDEX NAME)



● HF

5 H_2O

RN 439610-52-3 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride, undecahydrate (9CI) (CA INDEX NAME)



● HCl

11 H_2O

IT **3727-95-5 273720-80-2**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)
RN 3727-95-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 273720-80-2 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride (9CI) (CA INDEX NAME)



● HF

IT **3717-40-6 439610-53-4**
RL: PRP (Properties)
(hydrogen bonding and FT-NMR study of hydration of N,N-dimethyl-1-adamantamine-hydrogen fluoride and N,N-dimethyl-1-adamantylammonium chloride)
RN 3717-40-6 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 439610-53-4 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, conjugate acid (9CI) (CA INDEX NAME)



● H^+

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN
AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is a mol. species which does not dissoc. in aq. soln., and which contains a **covalent** three-center NHF bond. This compd. forms three hydrates, a stoichiometric liq. pentahydrate, a reasonably stable cryst. trihydrate, and an ephemeral cryst. monohydrate. IR spectra and ab initio geometry optimization demonstrate that the monohydrate forms a dimeric cluster of Ci symmetry with a C2h planar (H2O.cntdot.F)2 unit sandwiched between bound amine

units. This structure contains 4HOHF, 2CHF, 4CHOH2, and 2NHF hydrogen bonds. The assocn. energies of these bonds are estd. by MO methods, and the possible reasons for the extraordinary instability of the (H2O.cntdot.F)2 unit relative to similar units in quaternary ammonium fluoride monohydrates are discussed.

ACCESSION NUMBER: 2002:943723 HCAPLUS
DOCUMENT NUMBER: 138:262055
TITLE: Hydrogen bonding. Part 81. Infrared and molecular orbital study of the hydrates of N,N-dimethyl-1-adamantamine-hydrogen fluoride
AUTHOR(S): Harmon, Kenneth M.; Nicolla, Eranda; Benning, Nicole M.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309-4401, USA
SOURCE: Journal of Molecular Structure (2002), 642(1-3), 85-91
CODEN: JMOSB4; ISSN: 0022-2860
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is a mol. species which does not dissoc. in aq. soln., and which contains a **covalent** three-center NHF bond. This compd. forms three hydrates, a stoichiometric liq. pentahydrate, a reasonably stable cryst. trihydrate, and an ephemeral. . .

IT **439610-51-2 439610-54-5 502704-71-4**
RL: PRP (Properties)
(IR and MO study of hydrogen bonding in hydrates of N,N-di-Me-1-adamantamine-hydrogen fluoride)

IT **439610-51-2 439610-54-5 502704-71-4**
RL: PRP (Properties)
(IR and MO study of hydrogen bonding in hydrates of N,N-di-Me-1-adamantamine-hydrogen fluoride)

RN 439610-51-2 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, pentahydrate (9CI) (CA INDEX NAME)



● HF

5 H_2O

RN 439610-54-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, monohydrate (9CI) (CA INDEX NAME)



● HF

● H_2O

RN 502704-71-4 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride, trihydrate (9CI) (CA INDEX NAME)



● HF

3 H_2O

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 27 USPATFULL on STN
AB The present invention relates to the use of compounds capable of displacing tritiated cis-N-cyclohexyl-N-ethyl [3-(3-chloro-4-cyclohexylphenyl)-allyl]amine from its receptors for the preparation of pharmaceutical compositions intended to combat cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:75443 USPATFULL
TITLE: Use of amines to produce drugs for preventing tumor cell proliferation
INVENTOR(S): Breliere, Jean Claude, Montpellier, France
Ferrara, Pascual, Avignonet Lauragais, France
Lebouteiller, Christine, Pechabou, France
Paul, Raymond, Saint Gely du Fesc, France
Rosenfeld, Jorge, Baziege, France
Van Broeck, Didier, Murviel les Montpellier, France
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6235791	B1	20010522	
	WO 9804251		19980205	
APPLICATION INFO.:	US 1999-230643		19990412	(9)
	WO 1997-FR1409		19970728	
			19990412	PCT 371 date
			19990412	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-9531	19960729

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Alexander, Michael D.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM or RB and RC together form a --CH.dbd. bridge, and the bond with **links** it to the aromatic ring is a single bond and, in this case, A.sub.c represents a CH.sub.2 group and RA. . .

SUMM the carbonyl being **linked** to the oxygen and the bond connecting A.sub.c to the carbon bearing the side chain is a double bond, and,. . .

SUMM . . . from H, OH, (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, halogen and cyano; V.sub.1 and V.sub.2 together form a double bond **linked** to an oxygen atom or alternatively a hydroxyimino radical N--OH, or alternatively are connected as an ethylenedioxy chain --O--CH.sub.2 --CH.sub.2. . .

IT 132173-04-7P 132173-06-9P 132173-12-7P 132186-55-1P 202720-04-5P
202720-06-7P 202720-08-9P 202720-09-0P 202720-10-3P
202720-11-4P 202720-12-5P 202720-13-6P 202720-14-7P
202720-15-8P 202720-16-9P 202720-17-0P 202720-18-1P 202720-19-2P
202720-20-5P 202720-21-6P 202720-22-7P 202720-23-8P 202720-24-9P
202720-25-0P 202720-26-1P 202720-27-2P 202720-28-3P 202720-29-4P
202720-30-7P 202720-31-8P 202720-32-9P 202720-33-0P 202720-34-1P
202720-35-2P 202720-36-3P 202720-37-4P 202720-38-5P 202720-39-6P
202720-40-9P **202720-41-0P** 202720-42-1P 202720-43-2P
202720-44-3P 202720-45-4P 202720-46-5P
(prepn. of N-[(cyclohexylphenyl)alk(en)yl]piperidines and analogs as tumor cell proliferation inhibitors)

IT **202720-11-4P 202720-41-0P**
(prepn. of N-[(cyclohexylphenyl)alk(en)yl]piperidines and analogs as tumor cell proliferation inhibitors)

RN 202720-11-4 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-amine, N-[3-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-, hydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 202720-41-0 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-amine, N-[3-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 5 OF 27 USPATFULL on STN
AB The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:8090 USPATFULL
TITLE:	Therapeutic guanidines
INVENTOR(S):	Goldin, Stanley M., Lexington, MA, United States Fischer, James B., Cambridge, MA, United States Knapp, Andrew Gannett, Salem, MA, United States Reddy, N. Laxma, Malden, MA, United States Berlove, David, Cambridge, MA, United States Durant, Graham J., Cambridge, MA, United States Katragadda, Subbarao, Belmont, MA, United States Hu, Lain-Yen, Bedford, MA, United States Magar, Sharad, Somerville, MA, United States Fan, Wenhong, Rockey Hill, CT, United States Yost, Elizabeth, Waltham, MA, United States Guo, Jun Qing, Waltham, MA, United States
PATENT ASSIGNEE(S):	Cambridge NeuroScience, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6174924	B1	20010116
APPLICATION INFO.:	US 1995-462013		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1995-US1536, filed on 3 Feb 1995 Continuation-in-part of Ser. No. US 1994-191793, filed on 3 Feb 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: O'Sullivan, Peter
LEGAL REPRESENTATIVE: Dike, Bronstein, Roberts & Cushman, LLP, Conlin, David G., Corless, Peter F.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 4248
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . leading to a large and rapid increase in intracellular Ca.sup.2+. A subclass of non-NMDA receptors has been found to be **linked** to a Ca-permeable cation channel [Sommer, B., and Seeburg, P. H., Trends Pharmacol. Sci. 13:291-296 (1992)]. Although non-NMDA receptors are in most other instances **linked** to cation channels that largely exclude calcium, they can indirectly promote Ca.sup.2+ entry into neurons by depolarizing the cell membrane,. . .

SUMM Non-NMDA receptors constitute a broad category of postsynaptic receptor sites which, as is the case for NMDA receptors, are directly **linked** to ion channels. Specifically, the receptor sites are physically part of specific ion channel proteins. Non-NMDA receptors have been broadly. . .

SUMM . . . NMDA antagonists may largely be the artifactual result of induction of hypothermia rather that due to direct inhibition of NMDA receptor-**linked** Ca entry into brain neurons [Buchan, A. et al., J. Neurosci., 11 (1991) 1049-1056]. In contrast, the competitive non-NMDA receptor. . .

SUMM . . . group as defined for R.sup.1 above; or R.sup.2 and R.sup.3 are taken together to form a substituted or unsubstituted alkylene **linkage** of from 2 to about 6 carbon atoms; and pharmaceutically acceptable salts thereof.

SUMM . . . the invention, also include those compounds wherein R.sup.2 and R.sup.3 are taken together to form a substituted or unsubstituted alkylene **linkage** of from 3 to about 6 carbon atoms, particularly compounds with an alkylene **linkage** of 3 carbon atoms as represented of the following Formula IV(B): ##STR11##

SUMM . . . t-butyl, iso-butyl, sec-butyl, pentyl, hexyl, heptyl, etc. Preferred alkenyl and alkynyl groups include those groups having one or more unsaturated **linkages**, preferably one or two unsaturated **linkages** and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms. Each of the terms. . . groups are generally more preferred. Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen **linkages** and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1. . . benzyloxy (i.e., C.sub.6 H.sub.5 CH.sub.2 O--) are preferred aralkoxy groups. Preferred thioalkyl groups include groups having one or more thioether **linkages** and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1. . .

SUMM . . . atoms or from 1 to about 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated **linkages**

and from 2 to about 12 carbon atoms or from 2 to about 6 carbon atoms; alkoxy groups such as those groups having one or more oxygen **linkages** and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; thioalkyl groups such as those groups having one or more thioether **linkages** and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as. . .

SUMM Compounds of Formula IV where R.sup.2 and R.sup.3 taken together form a substituted or unsubstituted alkylene **linkage** of from 2 to about 6 carbon atoms can be prepared as exemplified by the procedure disclosed in Example 8. . .

IT

104919-99-5P	155270-61-4P	167310-63-6P	167313-63-5P	169958-59-2P
171764-75-3P	171764-76-4P	171764-77-5P	171764-78-6P	171764-79-7P
171764-81-1P	171764-82-2P	171764-83-3P	171764-84-4P	171764-85-5P
171764-86-6P	171764-87-7P	171764-88-8P	171764-89-9P	171764-90-2P
171764-91-3P	171764-92-4P	171764-93-5P	171764-94-6P	171764-95-7P
171764-96-8P	171764-97-9P	171764-98-0P	171764-99-1P	171765-00-7P
171765-01-8P	171765-03-0P	171765-04-1P	171765-05-2P	171765-06-3P
171765-07-4P	171765-08-5P	171765-09-6P	171765-10-9P	171765-12-1P
171765-13-2P	171765-14-3P	171765-15-4P	171765-16-5P	171765-17-6P
171765-18-7P	171765-19-8P	171765-20-1P	171765-21-2P	171765-22-3P
171765-23-4P	171765-24-5P	171765-25-6P	171765-26-7P	171765-27-8P
171765-28-9P	171765-29-0P	171765-30-3P	171765-31-4P	171765-32-5P
171765-33-6P	171765-34-7P	171765-35-8P	171765-36-9P	171765-37-0P
171765-38-1P	171765-39-2P	171765-40-5P	171765-41-6P	171765-42-7P
171765-43-8P	171765-44-9P	171765-45-0P	171765-46-1P	171765-47-2P
171765-48-3P	171765-49-4P	171765-50-7P	171765-51-8P	171765-52-9P
171765-53-0P	171765-54-1P	171765-55-2P	171765-56-3P	171765-57-4P
171765-58-5P	171765-59-6P	171765-60-9P	171765-61-0P	171765-62-1P
171765-63-2P	171765-64-3P	171765-65-4P	171765-66-5P	171765-67-6P
171765-68-7P	171765-69-8P	171765-70-1P	171765-71-2P	171765-72-3P
171765-73-4P	171765-74-5P	171765-75-6P	171765-76-7P	171765-77-8P
171765-78-9P	171765-79-0P	171765-80-3P	171765-81-4P	171765-82-5P
171765-83-6P	171765-84-7P	171765-85-8P	171765-86-9P	171765-87-0P
171765-88-1P	171765-89-2P	171765-90-5P	171765-91-6P	171765-92-7P
171765-93-8P	171765-94-9P	171765-95-0P	171765-96-1P	171765-97-2P
171765-98-3P	171765-99-4P	171766-00-0P	171766-01-1P	171766-02-2P
171766-03-3P	171766-04-4P	171766-05-5P	171766-06-6P	171766-07-7P
171766-08-8P	171766-09-9P	171766-10-2P	171766-11-3P	171766-12-4P
171766-13-5P	171766-14-6P	171766-15-7P	171766-16-8P	171766-17-9P
171766-18-0P	171766-19-1P	171766-20-4P	171766-21-5P	171766-22-6P
171766-23-7P	171766-24-8P	171766-25-9P	171766-26-0P	171766-27-1P
171766-28-2P	171766-29-3P	171766-30-6P	171766-31-7P	171766-32-8P
171766-33-9P	171766-34-0P	171766-35-1P	171766-36-2P	171766-37-3P
171766-38-4P	171766-39-5P	171766-40-8P	171766-41-9P	171766-42-0P
171766-43-1P	171766-44-2P	171766-45-3P	171766-46-4P	171766-47-5P
171766-48-6P	171766-49-7P	171766-50-0P	171766-51-1P	171766-52-2P
171766-53-3P	171766-54-4P	171766-55-5P	171766-56-6P	171766-57-7P
171766-58-8P	171766-59-9P	171766-60-2P	171766-61-3P	171766-62-4P
171766-63-5P	171766-64-6P	171766-65-7P	171766-66-8P	171766-67-9P
171766-68-0P	171766-69-1P	171766-70-4P	171766-71-5P	171766-72-6P
171766-73-7P	171766-74-8P	171766-75-9P	171766-76-0P	171766-77-1P
171766-78-2P	171766-79-3P	171766-80-6P	171766-81-7P	
171766-82-8P	**171766-83-9P**	171766-84-0P	171766-85-1P	
171766-86-2P	171766-87-3P	171766-88-4P	171766-89-5P	
171766-90-8P	**171766-91-9P**	171766-92-0P	171766-93-1P	
171766-94-2P	171766-95-3P	171766-96-4P	171766-97-5P	171766-98-6P
171766-99-7P	171767-00-3P	171767-01-4P	171767-02-5P	171767-03-6P
171767-04-7P	171767-05-8P	171767-06-9P		

(prepn. of arylguanidines as glutamate release inhibitors)

IT 171767-07-0P 171767-08-1P 171767-09-2P 171767-10-5P 171767-11-6P
171767-12-7P 171767-13-8P 171767-14-9P 171767-15-0P 171767-16-1P
171767-17-2P 171767-18-3P 171767-19-4P 171767-20-7P 171767-21-8P
171767-22-9P 171767-23-0P 171767-24-1P 171767-25-2P 171767-26-3P
171767-27-4P 171767-28-5P 171767-29-6P 171767-30-9P 171767-31-0P
171767-32-1P 171767-33-2P 171767-34-3P 171767-35-4P 171767-36-5P
171767-37-6P 171767-38-7P 171767-39-8P 171767-40-1P 171767-41-2P
171767-42-3P 171767-43-4P 171767-44-5P 171767-45-6P 171767-46-7P
171767-47-8P 171767-48-9P 171767-49-0P 171767-50-3P 171767-51-4P
171767-52-5P 171767-53-6P 171767-54-7P 171767-55-8P 171767-56-9P
171767-57-0P 171767-58-1P 171767-59-2P 171767-60-5P 171767-61-6P
171767-62-7P 171767-63-8P 171767-64-9P 171767-65-0P 171767-66-1P
171767-67-2P 171767-68-3P 171767-69-4P 171767-70-7P 171767-71-8P
171767-72-9P 171767-73-0P 171767-74-1P 171767-75-2P 171767-76-3P
171767-77-4P 171767-78-5P 171767-79-6P 171767-80-9P 171767-81-0P
171767-82-1P 171767-83-2P 171767-84-3P 171767-85-4P 171767-86-5P
171767-87-6P 171767-88-7P 171767-89-8P 171767-90-1P 171767-91-2P
171767-92-3P 171767-93-4P 171767-94-5P 171767-95-6P 171767-96-7P
171767-97-8P 171767-98-9P 171767-99-0P 171768-00-6P 171768-01-7P
171768-02-8P 171768-03-9P 171768-04-0P 171768-05-1P 171768-06-2P
171768-07-3P 171768-08-4P 171768-09-5P 171768-10-8P 171768-11-9P
171768-12-0P 171768-13-1P 171768-14-2P 171768-15-3P 171768-16-4P
171768-17-5P 171768-18-6P 171768-19-7P 171768-20-0P 171768-21-1P
171768-22-2P 171768-23-3P 171768-24-4P 171768-25-5P 171768-26-6P
171768-27-7P 171768-28-8P 171768-29-9P 171768-30-2P 171768-31-3P
171768-32-4P 171768-33-5P 171768-34-6P 171768-35-7P 171768-36-8P
171768-37-9P 171768-38-0P 171768-39-1P 171768-40-4P 171768-41-5P
171768-52-8P 171768-53-9P 171768-54-0P 171864-64-5P
171864-65-6P 171864-66-7P 171864-67-8P 171864-68-9P 171864-69-0P

(prepn. of arylguanidines as glutamate release inhibitors)

IT **171766-82-8P 171766-83-9P 171766-90-8P**
171766-91-9P 171768-52-8P 171768-53-9P

(prepn. of arylguanidines as glutamate release inhibitors)

RN 171766-82-8 USPATFULL

CN Guanidine, N'-1-anthracenyl-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 171766-83-9 USPATFULL

CN Guanidine, N-1-anthracenyl-N,N'-dimethyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 171766-90-8 USPATFULL
CN Guanidine, N-methyl-N'-1-phenanthrenyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 171766-91-9 USPATFULL
CN Guanidine, N,N'-dimethyl-N-1-phenanthrenyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 171768-52-8 USPATFULL
CN Guanidine, N'-9H-fluoren-1-yl-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 171768-53-9 USPATFULL
CN Guanidine, N-9H-fluoren-1-yl-N,N'-dimethyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 27 USPATFULL on STN
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:4747 USPATFULL
TITLE:	Compounds having effects on serotonin-related systems
INVENTOR(S):	Audia, James E., Indianapolis, IN, United States Hibschman, David J., Bargersville, IN, United States Krushinski, Jr., Joseph H., Indianapolis, IN, United States Mabry, Thomas E., Indianapolis, IN, United States Nissen, Jeffrey S., Fishers, IN, United States Rasmussen, Kurt, Fishers, IN, United States Rocco, Vincent P., Indianapolis, IN, United States Schaus, John M., Zionsville, IN, United States Thompson, Dennis C., Indianapolis, IN, United States Wong, David T., Indianapolis, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172073	B1	20010109
APPLICATION INFO.:	US 1998-49837		19980327 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789 Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lentz, Nelsen L.		
NUMBER OF CLAIMS:	8		

EXEMPLARY CLAIM: 1
LINE COUNT: 5343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 ethylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT 55581-45-8P 73889-11-9P 180156-51-8P 180156-53-0P 180156-54-1P
180156-56-3P 180156-58-5P 180156-60-9P 180156-61-0P 180156-63-2P
180156-65-4P 180156-67-6P 180156-69-8P 180156-71-2P 180156-73-4P
180156-75-6P 180156-77-8P 180156-79-0P 180156-81-4P 180156-83-6P
180156-85-8P 180156-87-0P 180156-89-2P 180156-91-6P 180156-92-7P
180156-94-9P 180156-96-1P 180156-98-3P 180157-00-0P 180157-02-2P
180157-04-4P 180157-06-6P 180157-08-8P 180157-10-2P 180157-12-4P
180157-14-6P 180157-16-8P 180157-18-0P 180157-20-4P 180157-22-6P
180157-24-8P 180157-26-0P 180157-28-2P 180157-30-6P 180157-32-8P
180157-34-0P 180157-36-2P 180157-38-4P 180157-40-8P 180157-42-0P
180157-44-2P 180157-46-4P 180157-48-6P 180157-50-0P 180157-52-2P
180157-54-4P 180157-56-6P 180157-58-8P 180157-60-2P 180157-62-4P
180157-64-6P 180157-66-8P 180157-68-0P 180157-70-4P 180157-72-6P
180157-74-8P 180157-76-0P 180157-78-2P 180157-80-6P 180157-82-8P
180157-84-0P 180157-86-2P 180157-88-4P 180157-90-8P 180157-92-0P
180157-94-2P 180157-95-3P 180157-96-4P 180157-98-6P 180158-00-3P
180158-02-5P 180158-04-7P 180158-06-9P 180158-08-1P 180158-10-5P
180158-12-7P 180158-13-8P 180158-15-0P 180158-17-2P 180158-19-4P
180158-20-7P 180158-22-9P 180158-24-1P 180158-26-3P 180158-28-5P
180158-30-9P 180158-32-1P 180158-34-3P 180158-36-5P 180158-38-7P
180158-39-8P 180158-40-1P 180158-41-2P 180158-42-3P 180158-43-4P
180158-44-5P 180158-45-6P 180158-46-7P 180158-47-8P 180158-48-9P
180158-49-0P 180158-50-3P 180158-51-4P **180158-52-5P**
180158-53-6P 180158-54-7P 180158-55-8P 180158-57-0P 180158-58-1P
180158-59-2P 180158-60-5P 180158-61-6P 180158-63-8P 180158-65-0P
180158-67-2P 180158-69-4P 180158-71-8P 180158-73-0P 180158-75-2P
180158-77-4P 180158-79-6P 180158-81-0P 180158-83-2P 180158-85-4P
180158-87-6P 180158-89-8P 180158-90-1P 180158-91-2P 180158-92-3P
180158-93-4P 180158-94-5P 180158-95-6P 180158-96-7P 180158-97-8P
180158-98-9P 180158-99-0P 180159-00-6P 180159-01-7P 180159-03-9P
180159-05-1P 180159-07-3P 180159-09-5P 180159-11-9P 180159-12-0P
180159-13-1P 180159-14-2P 180159-15-3P 180159-16-4P 180159-17-5P
180159-18-6P 180159-19-7P 180159-20-0P 180159-21-1P 180159-22-2P
180159-23-3P 180159-24-4P 180159-25-5P 180159-26-6P 180159-27-7P
180159-28-8P 180159-29-9P 180159-31-3P 180159-33-5P 180159-35-7P
180159-37-9P 180159-39-1P 180159-41-5P 180159-43-7P 180159-45-9P
180159-47-1P 180159-49-3P 180159-51-7P 180159-53-9P 180159-55-1P
180159-57-3P 180159-59-5P 180159-61-9P 180159-63-1P 180159-65-3P

180159-67-5P 180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P
180159-77-7P 180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P
180159-87-9P 180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P
180159-95-9P 180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P
180160-00-3P 180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P
180160-05-8P 180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P
180160-10-5P 180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P
180160-15-0P 180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P
180160-20-7P 180160-21-8P 180160-22-9P 180160-23-0P 180160-24-1P
180160-25-2P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

IT 180160-26-3P 180160-27-4P 180160-28-5P 180160-29-6P 180160-30-9P
180160-31-0P 180160-32-1P **180160-33-2P** 180160-34-3P
180160-35-4P 180160-36-5P 180271-36-7P
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

IT **180158-52-5P 180160-33-2P**
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

RN 180158-52-5 USPATFULL
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 180160-33-2 USPATFULL
CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 7 OF 27 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:41028 USPATFULL

TITLE: Method of synergistic treatment for benign prostatic hyperplasia

INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
Stoner, Elizabeth, Westfield, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046183		20000404
APPLICATION INFO.:	US 1998-27105		19980220 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-428595, filed on 25 Apr 1995, now patented, Pat. No. US 5753641 which is a continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 20 Mar 1991, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Criares, Theodore J.

LEGAL REPRESENTATIVE: Fitch, Catherine D.

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

LINE COUNT: 5342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are **linked** together are cyclopentane, cyclohexane or a benzene ring; and

IT 98319-25-6P 98319-28-9P 98319-29-0P 103335-45-1P 103335-46-2P
103335-48-4P 103335-56-4P 103335-57-5P 103497-68-3P 119169-78-7P
119347-91-0P 119347-96-5P 119348-05-9P 133216-44-1P 134067-56-4P
134067-64-4P 134217-16-6P 134217-17-7P 138715-91-0P 139229-87-1P
139229-88-2P 139229-89-3P 139229-90-6P 139229-91-7P 139229-92-8P
139229-93-9P 139229-94-0P 139229-95-1P 139229-97-3P 139230-03-8P
139230-04-9P 139255-63-3P 139344-08-4P 139344-09-5P 139512-72-4P
139512-73-5P 139512-75-7P 139512-76-8P 139512-77-9P 139512-78-0P
139512-79-1P 139512-80-4P 139523-47-0P 139539-84-7P 139755-31-0P

144879-06-1P 144879-08-3P 144879-10-7P 144879-16-3P 144879-17-4P
144879-18-5P 144879-21-0P 144879-25-4P 144879-27-6P 144879-29-8P
144879-32-3P 144879-33-4P 144879-34-5P 144879-35-6P 144879-36-7P
144879-37-8P 144879-38-9P 144879-39-0P 144879-40-3P 144879-41-4P
144879-48-1P 144879-50-5P 144879-55-0P 144879-60-7P 145191-61-3P
146032-67-9P 146032-69-1P 146057-96-7P 146142-97-4P
146143-98-8P
(prepn. of)

IT **146032-67-9P**
(prepn. of)

RN 146032-67-9 USPATFULL

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB N,N-dimethyl-1-adamantamine-hydrogen fluoride is not a tertiary ammonium salt. It is a highly cryst. mol. complex whose IR spectrum demonstrates the presence of **covalent** type three-center N-H-F bonds. The compd. is obtained from ethanol-water soln., and FT-NMR spectra indicate that it is stable in aq. soln. An ab initio MO study of this and potentially similar tertiary amine-hydrogen fluoride complexes suggests a value of about -18 kcal mol-1 for the formation of N-H-F bond, and in addn. predicts that secondary C-H.cntdot..cntdot..cntdot.F hydrogens bonding by .beta.-hydrogens of the amine may be present in such compds.

ACCESSION NUMBER: 2000:220952 HCAPLUS
DOCUMENT NUMBER: 133:30471
TITLE: Hydrogen bonding. Part 73. IR, NMR, and ab initio molecular orbital study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a crystalline, H2O stable compound with a three-center N-H-F bond
AUTHOR(S): Harmon, K. M.; Webb, A. C.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, USA
SOURCE: Journal of Molecular Structure (2000), 522, 79-86
CODEN: JMOSB4; ISSN: 0022-2860
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB . . . is not a tertiary ammonium salt. It is a highly cryst. mol. complex whose IR spectrum demonstrates the presence of **covalent** type three-center N-H-F bonds. The compd. is obtained from ethanol-water soln., and FT-NMR spectra indicate that it is stable in. . .

IT **273720-80-2**
RL: PRP (Properties)
(IR, NMR, and ab initio MO study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a cryst., H2O stable compd. with a three-center N-H-F bond)

IT **273720-80-2**
RL: PRP (Properties)
(IR, NMR, and ab initio MO study of N,N-dimethyl-1-adamantamine-hydrogen fluoride, a cryst., H2O stable compd. with a three-center N-H-F bond)

RN 273720-80-2 HCAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-dimethyl-, hydrofluoride (9CI) (CA INDEX NAME)



● HF

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 27 USPATFULL on STN

AB Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:54885 USPATFULL

TITLE: Method of treatment for benign prostatic hyperplasia

INVENTOR(S): Gormley, Glenn J., Westfield, NJ, United States
Stoner, Elizabeth, Westfield, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 5753641 19980519
APPLICATION INFO.: US 1995-428595 19950425 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-201063, filed on 24 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-22805, filed on 22 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-846153, filed on 11 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-672511, filed on 10 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Fitch, Catherine D., Nicholson, William H.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 5371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . or the two R.sup.1 's and the carbon atoms of the benzene ring to which the two R.sup.1 's are **linked** together are cyclopentane, cyclohexane or a benzene ring; and
IT 98319-25-6P 98319-28-9P 98319-29-0P 103335-45-1P 103335-46-2P
103335-48-4P 103335-56-4P 103335-57-5P 103497-68-3P 119169-78-7P
119347-91-0P 119347-96-5P 119348-05-9P 133216-44-1P 134067-56-4P
134067-64-4P 134217-16-6P 134217-17-7P 138715-91-0P 139229-87-1P
139229-88-2P 139229-89-3P 139229-90-6P 139229-91-7P 139229-92-8P
139229-93-9P 139229-94-0P 139229-95-1P 139229-97-3P 139230-03-8P
139230-04-9P 139255-63-3P 139344-08-4P 139344-09-5P 139512-72-4P
139512-73-5P 139512-75-7P 139512-76-8P 139512-77-9P 139512-78-0P
139512-79-1P 139512-80-4P 139523-47-0P 139539-84-7P 139755-31-0P
144879-06-1P 144879-08-3P 144879-10-7P 144879-16-3P 144879-17-4P
144879-18-5P 144879-21-0P 144879-25-4P 144879-27-6P 144879-29-8P
144879-32-3P 144879-33-4P 144879-34-5P 144879-35-6P 144879-36-7P
144879-37-8P 144879-38-9P 144879-39-0P 144879-40-3P 144879-41-4P
144879-48-1P 144879-50-5P 144879-55-0P 144879-60-7P 145191-61-3P
146032-67-9P 146032-69-1P 146057-96-7P 146142-97-4P
146143-98-8P
(prepn. of)
IT **146032-67-9P**
(prepn. of)
RN 146032-67-9 USPATFULL
CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-N,4a,6a-trimethyl-2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 10 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:42357 USPATFULL
TITLE: Compounds having effects on serotonin-related systems
INVENTOR(S): Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741789		19980421
APPLICATION INFO.:	US 1995-467434		19950606 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Palmberg, Arleen, Boone, David E.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 5902

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as

dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
180158-49-0P	180158-50-3P	180158-51-4P	**180158-52-5P**	
180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P
180159-39-1P	180159-41-5P	180159-43-7P	180159-45-9P	180159-47-1P
180159-49-3P	180159-50-6P	180159-51-7P	180159-53-9P	180159-55-1P
180159-57-3P	180159-59-5P	180159-63-1P	180159-65-3P	180159-67-5P
180159-69-7P	180159-71-1P	180159-73-3P	180159-75-5P	180159-77-7P
180159-79-9P	180159-81-3P	180159-83-5P	180159-85-7P	180159-87-9P
180159-89-1P	180159-91-5P	180159-93-7P	180159-94-8P	180159-95-9P
180159-96-0P	180159-97-1P	180159-98-2P	180159-99-3P	180160-00-3P
180160-01-4P	180160-02-5P	180160-03-6P	180160-04-7P	180160-05-8P
180160-06-9P	180160-07-0P	180160-08-1P	180160-09-2P	180160-10-5P
180160-11-6P	180160-12-7P	180160-13-8P	180160-14-9P	180160-15-0P
180160-16-1P	180160-17-2P	180160-18-3P	180160-19-4P	180160-20-7P
180160-21-8P	180271-36-7P	185255-45-2P	185255-47-4P	185255-49-6P
185255-51-0P	185255-53-2P	185255-55-4P	185255-67-8P	185255-71-4P
185255-73-6P	190785-69-4P	190786-32-4P	190786-36-8P	190788-23-9P

(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

IT **180158-52-5P**

(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L16 ANSWER 11 OF 27 USPATFULL on STN

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:38539 USPATFULL
TITLE:	Compounds having effects on serotonin-related systems
INVENTOR(S):	Audia, James E., Indianapolis, IN, United States Hibschman, David J., Bargersville, IN, United States Krushinski, Jr., Joseph H., Indianapolis, IN, United States Mabry, Thomas E., Indianapolis, IN, United States Nissen, Jeffrey S., Fishers, IN, United States Rasmussen, Kurt, Fishers, IN, United States Rocco, Vincent P., Indianapolis, IN, United States Schaus, John M., Zionsville, IN, United States Thompson, Dennis C., Indianapolis, IN, United States Wong, David T., Indianapolis, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627196		19970506
APPLICATION INFO.:	US 1995-468948		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Bottino, Anthony
LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
LINE COUNT: 5947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

180156-51-8P	180156-54-1P	180156-56-3P	180156-60-9P	180156-61-0P
180156-63-2P	180156-67-6P	180156-69-8P	180156-73-4P	180156-75-6P
180156-77-8P	180156-79-0P	180156-81-4P	180156-83-6P	180156-85-8P
180156-87-0P	180156-89-2P	180156-91-6P	180156-94-9P	180156-96-1P
180156-98-3P	180157-00-0P	180157-02-2P	180157-04-4P	180157-06-6P
180157-08-8P	180157-10-2P	180157-12-4P	180157-14-6P	180157-16-8P
180157-18-0P	180157-20-4P	180157-22-6P	180157-24-8P	180157-26-0P
180157-28-2P	180157-30-6P	180157-34-0P	180157-36-2P	180157-38-4P
180157-40-8P	180157-41-9P	180157-42-0P	180157-44-2P	180157-46-4P
180157-50-0P	180157-52-2P	180157-54-4P	180157-56-6P	180157-58-8P
180157-60-2P	180157-62-4P	180157-64-6P	180157-66-8P	180157-68-0P
180157-70-4P	180157-71-5P	180157-72-6P	180157-73-7P	180157-74-8P
180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-01-4P
180158-02-5P	180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P
180158-12-7P	180158-13-8P	180158-15-0P	180158-17-2P	180158-19-4P
180158-20-7P	180158-22-9P	180158-24-1P	180158-26-3P	180158-28-5P
180158-30-9P	180158-32-1P	180158-34-3P	180158-36-5P	180158-38-7P
180158-39-8P	180158-40-1P	180158-41-2P	180158-42-3P	180158-43-4P
180158-44-5P	180158-45-6P	180158-46-7P	180158-47-8P	180158-48-9P
180158-49-0P	180158-50-3P	180158-51-4P	**180158-52-5P**	
180158-53-6P	180158-55-8P	180158-57-0P	180158-58-1P	180158-59-2P
180158-61-6P	180158-63-8P	180158-65-0P	180158-67-2P	180158-69-4P
180158-71-8P	180158-73-0P	180158-75-2P	180158-77-4P	180158-79-6P
180158-81-0P	180158-83-2P	180158-85-4P	180158-87-6P	180158-89-8P
180158-91-2P	180158-93-4P	180158-94-5P	180158-96-7P	180158-97-8P
180158-98-9P	180159-00-6P	180159-01-7P	180159-03-9P	180159-07-3P
180159-09-5P	180159-12-0P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-25-5P	180159-26-6P	180159-27-7P
180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P	180159-37-9P

180159-39-1P 180159-41-5P 180159-43-7P 180159-45-9P 180159-47-1P
180159-49-3P 180159-50-6P 180159-51-7P 180159-53-9P 180159-55-1P
180159-57-3P 180159-59-5P 180159-63-1P 180159-65-3P 180159-67-5P
180159-69-7P 180159-71-1P 180159-73-3P 180159-75-5P 180159-77-7P
180159-79-9P 180159-81-3P 180159-83-5P 180159-85-7P 180159-87-9P
180159-89-1P 180159-91-5P 180159-93-7P 180159-94-8P 180159-95-9P
180159-96-0P 180159-97-1P 180159-98-2P 180159-99-3P 180160-00-3P
180160-01-4P 180160-02-5P 180160-03-6P 180160-04-7P 180160-05-8P
180160-06-9P 180160-07-0P 180160-08-1P 180160-09-2P 180160-10-5P
180160-11-6P 180160-12-7P 180160-13-8P 180160-14-9P 180160-15-0P
180160-16-1P 180160-17-2P 180160-18-3P 180160-19-4P 180160-20-7P
180160-21-8P 180271-36-7P 185255-45-2P 185255-47-4P 185255-49-6P
185255-51-0P 185255-53-2P 185255-55-4P 185255-67-8P 185255-71-4P
185255-73-6P 190785-69-4P 190786-32-4P 190786-36-8P 190788-23-9P
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

IT **180158-52-5P**
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L16 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB New diacrylate monomers for cyclopolymn. were synthesized from the reaction of Et .alpha.-chloromethylacryalte (ECMA) and t-Bu .alpha.-bromomethylacrylate (TBBr) with aniline, adamantyl amine, t-Bu amine, cyanamide, and 4-tetradecyl aniline in yields of ca. 50-70%. Bulk and soln. polymns. with azobisisobutyronitrile (AIBN) at 60-85.degree.C gave sol. cyclopolymers with Mn and Mw ranging from 10,000-30,000 and 12,000-40,000, resp. The ECMA-cyanamide deriv. only gave crosslinked polymers. 1H and 13C soln. NMR indicated high cyclization efficiency (>93%). A prototype NLO polymer was synthesized from the reaction of the TBBr-aniline cyclopolymer with tetracyanoethylene. The p-hydroxyaniline deriv. of ECMA was synthesized and used for further derivatizations; for example, the benzoate ester was made and polymd. (Mn = 21,260 and Mw = 40,317). The ester groups of the TBBr-aniline polymer were hydrolyzed completely to give a polymer with both acid and base moieties. DSC thermograms showed glass transitions of 132.degree.C for the ECMA-aniline deriv., 1992.degree.C for the ECMA-adamantyl deriv., 53.degree.C for the

TBBr-tetradecylaniline deriv., and 120.degree.C for the ECMA-p-benzoylaniline deriv. The ECMA-t-Bu amine polymer showed no obvious Tg.

ACCESSION NUMBER: 1997:434444 HCAPLUS
DOCUMENT NUMBER: 127:162218
TITLE: Cyclopolymerization of amine-**linked** diacrylate monomers
AUTHOR(S): Avci, Duygu; Haynes, Camille; Mathias, Lon J.
CORPORATE SOURCE: Chem. Dep., Bogazici Univ., Istanbul, 80815, Turk.
SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1997), 35(10), 2111-2121
CODEN: JPACEC; ISSN: 0887-624X
PUBLISHER: Wiley
DOCUMENT TYPE: Journal
LANGUAGE: English

TI Cyclopolymerization of amine-**linked** diacrylate monomers
ST cyclopolymn amine **linked** diacrylate; nonlinear optical material acrylic cyclopolymer
IT Glass transition temperature
(cyclopolymn. and properties of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT Solubility
(cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT Polymerization
(cyclopolymn.; cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT IR spectra
NMR (nuclear magnetic resonance)
Nonlinear optical materials
(of amine-**linked** monomers and cyclopolymers from them)
IT Solvent effect
(on cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT 193527-64-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(attempted cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT 193527-67-2P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cyclopolymer; cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT 670-54-2DP, Tetracyanoethylene, reaction products with acrylic cyclopolymer 193527-61-6P **193527-62-7P** 193527-63-8P 193527-65-0P 193527-66-1P 193527-67-2DP, reaction products with tetracyanoethylene or hydrolyzed products **193527-68-3P** 193527-69-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(cyclopolymer; cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)
IT 193527-71-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate in monomer prepn.; cyclopolymn. of amine-**linked** diacrylate monomers)
IT 193527-52-5P **193527-53-6P** 193527-54-7P 193527-55-8P 193527-56-9P 193527-57-0P 193527-58-1P **193527-59-2P**

193527-60-5P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; cyclopolymn. of amine-**linked** diacrylate monomers)

IT 62-53-3, Benzenamine, reactions 75-64-9, reactions 98-88-4, Benzoyl chloride 123-30-8, p-Hydroxyaniline 420-04-2, Cyanamide 720-98-9, 4-Benzoyloxyaniline 768-94-5, 1-Adamantylamine 17435-77-7, Ethyl .alpha.-chloromethylacrylate 53913-96-5, tert-Butyl .alpha.-bromomethylacrylate 91323-12-5, 4-Tetradecylaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant in monomer prepn.; cyclopolymn. of amine-**linked** diacrylate monomers)

IT **193527-62-7P 193527-68-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(cyclopolymer; cyclopolymn. of amine-**linked** diacrylate monomers and prepn. of nonlinear optical materials)

RN 193527-62-7 HCAPLUS
CN 2-Propenoic acid, 2,2'-[(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)]bis-, diethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 193527-53-6
CMF C22 H33 N O4



RN 193527-68-3 HCAPLUS
CN 2-Propenoic acid, 2,2'-[(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)]bis-, bis(1,1-dimethylethyl) ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 193527-59-2
CMF C26 H41 N O4



IT **193527-53-6P 193527-59-2P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; cyclopolymn. of amine-**linked** diacrylate monomers)
RN 193527-53-6 HCAPLUS
CN 2-Propenoic acid, 2,2'-[(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 193527-59-2 HCAPLUS
CN 2-Propenoic acid, 2,2'-[(tricyclo[3.3.1.13,7]dec-1-ylimino)bis(methylene)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 27 USPATFULL on STN
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:106493 USPATFULL
TITLE: Compounds having effects on serotonin-related systems
INVENTOR(S): Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 5576321 19961119
APPLICATION INFO.: US 1995-468900 19950606 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Bottino, Anthony
LEGAL REPRESENTATIVE: Jones, Joseph A., Boone, David E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 5725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The subscripts r and s indicate that as many as 7 methylene groups may be in the **linker** alkylene chain. Thus, the chain is straight-chain alkyl from ethyl through heptyl, which may be substituted with the group X. . .

SUMM It may be noted again that bulky R.sup.3 groups such as dibenzocycloheptene or naphthyl may be **linked** in any reasonable orientation, as may substituent parts of the R.sup.3 group such as piperazinonyl.

SUMM The spiro-**linked** group of Formula VI represents structures of which the following are typical: ##STR17##

SUMM . . . Those substituents may represent phenyl or substituted phenyl groups or hydrogen, or R6 and R7 may combine to form a spiro-**linked** fluorenyl or dihydro anthracenyl group.

DETD Obsessive-compulsive disease appears in a great variety of degrees and symptoms, generally **linked** by the victim's uncontrollable urge to perform needless, ritualistic acts. Acts of acquiring, ordering, cleansing and the like, beyond any. . .

IT

55581-45-8P	73889-11-9P	180156-51-8P	180156-54-1P	180156-56-3P
180156-60-9P	180156-61-0P	180156-63-2P	180156-67-6P	180156-69-8P
180156-73-4P	180156-75-6P	180156-77-8P	180156-79-0P	180156-81-4P
180156-83-6P	180156-85-8P	180156-87-0P	180156-89-2P	180156-91-6P
180156-92-7P	180156-94-9P	180156-96-1P	180156-98-3P	180157-00-0P
180157-02-2P	180157-04-4P	180157-06-6P	180157-08-8P	180157-10-2P
180157-12-4P	180157-14-6P	180157-16-8P	180157-18-0P	180157-20-4P
180157-22-6P	180157-24-8P	180157-26-0P	180157-28-2P	180157-30-6P
180157-34-0P	180157-36-2P	180157-38-4P	180157-40-8P	180157-42-0P
180157-44-2P	180157-46-4P	180157-50-0P	180157-52-2P	180157-54-4P
180157-56-6P	180157-58-8P	180157-60-2P	180157-62-4P	180157-64-6P
180157-66-8P	180157-68-0P	180157-70-4P	180157-72-6P	180157-74-8P
180157-76-0P	180157-78-2P	180157-80-6P	180157-82-8P	180157-84-0P
180157-86-2P	180157-88-4P	180157-90-8P	180157-92-0P	180157-94-2P
180157-95-3P	180157-96-4P	180157-98-6P	180158-00-3P	180158-02-5P
180158-04-7P	180158-06-9P	180158-08-1P	180158-10-5P	180158-12-7P
180158-15-0P	180158-17-2P	180158-19-4P	180158-22-9P	180158-24-1P
180158-26-3P	180158-28-5P	180158-30-9P	180158-32-1P	180158-34-3P
180158-36-5P	180158-38-7P	180158-39-8P	180158-40-1P	180158-41-2P
180158-42-3P	180158-43-4P	180158-44-5P	180158-45-6P	180158-46-7P
180158-47-8P	180158-48-9P	180158-49-0P	180158-50-3P	180158-51-4P
180158-52-5P	180158-53-6P	180158-54-7P	180158-55-8P	
180158-57-0P	180158-58-1P	180158-59-2P	180158-60-5P	180158-61-6P
180158-65-0P	180158-67-2P	180158-69-4P	180158-71-8P	180158-73-0P
180158-75-2P	180158-77-4P	180158-79-6P	180158-81-0P	180158-83-2P
180158-85-4P	180158-87-6P	180158-89-8P	180158-90-1P	180158-91-2P
180158-92-3P	180158-93-4P	180158-94-5P	180158-97-8P	180158-98-9P
180159-01-7P	180159-03-9P	180159-07-3P	180159-09-5P	180159-11-9P

180159-12-0P	180159-13-1P	180159-14-2P	180159-15-3P	180159-16-4P
180159-17-5P	180159-18-6P	180159-19-7P	180159-20-0P	180159-21-1P
180159-22-2P	180159-23-3P	180159-24-4P	180159-25-5P	180159-26-6P
180159-27-7P	180159-28-8P	180159-29-9P	180159-31-3P	180159-33-5P
180159-34-6P	180159-35-7P	180159-37-9P	180159-39-1P	180159-41-5P
180159-43-7P	180159-45-9P	180159-47-1P	180159-49-3P	180159-51-7P
180159-53-9P	180159-55-1P	180159-57-3P	180159-59-5P	180159-63-1P
180159-65-3P	180159-67-5P	180159-69-7P	180159-71-1P	180159-73-3P
180159-75-5P	180159-77-7P	180159-79-9P	180159-81-3P	180159-83-5P
180159-84-6P	180159-85-7P	180159-87-9P	180159-89-1P	180159-91-5P
180159-93-7P	180159-94-8P	180159-95-9P	180159-96-0P	180159-97-1P
180159-98-2P	180159-99-3P	180160-00-3P	180160-01-4P	180160-02-5P
180160-03-6P	180160-04-7P	180160-05-8P	180160-06-9P	180160-07-0P
180160-08-1P	180160-09-2P	180160-10-5P	180160-11-6P	180160-12-7P
180160-13-8P	180160-14-9P	180160-15-0P	180160-16-1P	180160-17-2P
180160-18-3P	180160-19-4P	180160-20-7P	180160-22-9P	180160-23-0P
180160-24-1P	180160-25-2P	180160-26-3P	180160-27-4P	180160-28-5P
180160-29-6P	180160-30-9P	180160-31-0P	180160-32-1P	
180160-33-2P	180160-34-3P	180160-35-4P	180160-36-5P	
180271-36-7P	185255-45-2P			

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

IT **180158-52-5P 180160-33-2P**
(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

RN 180158-52-5 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 180160-33-2 USPATFULL

CN 2-Propanol, 1-(1H-indol-4-yloxy)-3-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 14 OF 27 USPATFULL on STN

AB There are provided a catalyst, a method for making this catalyst, and a process for using this catalyst in the alkylation of an isoparaffin with an olefin to provide an alkylate. The catalyst may be made from an as-synthesized material which, upon calcination, is capable of generating zeolites designated MCM-22. The as-synthesized material is then combined with a binder material, such as alumina, by an extrusion process. The uncalcined bound material may then be ammonium exchanged, followed by a calcination treatment. The as-synthesized material may also be swollen with a suitable swelling agent, such as a cetyltrimethylammonium compound, prior to the binding process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:41398 USPATFULL
TITLE: Catalyst and process for isoparaffin-olefin alkylation
INVENTOR(S): Chu, Cynthia T.-W., Moorestown, NJ, United States
Husain, Altaf, Marlton, NJ, United States
Keville, Kathleen M., Beaumont, TX, United States
Lissy, Daria N., Glen Mills, PA, United States
PATENT ASSIGNEE(S): Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5516962		19960514
APPLICATION INFO.:	US 1994-283928		19940801 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-42907, filed on 5 Apr 1993, now patented, Pat. No. US 5354718
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Pal, Asok
LEGAL REPRESENTATIVE: McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . used in this extrusion process usually includes a substantial amount of chemically bound water in the form of hydroxyl groups **covalently** bonded to aluminum atoms.

SUMM . . . strength by a condensation reaction, whereby hydroxyl groups associated with aluminum atoms in the binder react to form Al --O--Al **linkages** and to liberate water.

IT 108-91-8, Aminocyclohexane, reactions 111-49-9 505-66-8, 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2,

Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6**
116355-70-5
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)

IT **46244-96-6**
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 15 OF 27 USPATFULL on STN

AB There is provided a process for converting organic compounds using a catalyst comprising a pillared, layered crystalline oxide material. This material may be prepared by intercepting a swellable layered oxide before calcination. The intercepted material is swollen and pillared. If the material is not intercepted in this manner, it is transformed into a zeolite by calcination. The pillared material may have a large degree of catalytic activity, and it may have rather porous layers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:100052 USPATFULL
TITLE:	Organic conversion with a catalyst comprising a crystalline pillared oxide material
INVENTOR(S):	Kresge, Charles T., West Chester, PA, United States Roth, Wieslaw J., Sewell, NJ, United States Simmons, Kenneth G., Williamstown, NJ, United States Vartuli, James C., West Chester, NJ, United States
PATENT ASSIGNEE(S):	Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5364999		19941115
APPLICATION INFO.:	US 1993-28440		19930309 (8)
DISCLAIMER DATE:	20100727		
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-811384, filed on 20 Dec 1991, now patented, Pat. No. US 5229341 which is a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned , said Ser. No. US -811384 which is a continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned Ser. No. Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pal, Asok		
ASSISTANT EXAMINER:	Achutamurthy, P.		
LEGAL REPRESENTATIVE:	McKillop, Alexander J., Santini, Dennis P., Kenehan,		

Jr., Edward F.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-**linked** with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-**linking** agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross **linking** agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .
IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8, 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2, Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6** 116355-70-5
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)
IT **46244-96-6**
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)
RN 46244-96-6 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 16 OF 27 USPATFULL on STN
AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.A is ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 94:91061 USPATFULL
TITLE: Carbostyril oxytocin receptor antagonists
INVENTOR(S): Freidinger, Roger M., Lansdale, PA, United States
Pawluczyk, Joseph M., Warminster, PA, United States
Pettibone, Douglas J., Shalfont, PA, United States
Williams, Peter D., Harleysville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5356904		19941018	
APPLICATION INFO.:	US 1992-957491		19921007	(7)

10/016850

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Travers, Russell
LEGAL REPRESENTATIVE: Appollina, Mary A., DiPrima, Joseph F.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 7213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrlates and cross-**linked** or amphipathic block copolymers of hydrogels.

IT 131582-88-2P 131582-89-3P 131582-90-6P 131582-91-7P 131582-97-3P
131582-99-5P 131583-01-2P 131583-04-5P 131583-05-6P 131583-06-7P
131583-07-8P **131583-08-9P** 131583-09-0P 131583-10-3P
131583-11-4P 131583-13-6P 131583-14-7P 131583-15-8P 131583-17-0P
131583-18-1P 131583-19-2P 131583-20-5P 131583-21-6P 131583-23-8P
131583-24-9P 131583-26-1P 131583-27-2P 131583-28-3P 131583-29-4P
131583-30-7P 131583-31-8P 131583-33-0P 131583-34-1P 131583-35-2P
131583-36-3P 131583-37-4P 131583-38-5P 131583-39-6P 131583-40-9P
131583-41-0P 131583-42-1P 131583-43-2P 131583-44-3P 131583-45-4P
131583-46-5P 131583-49-8P 131583-50-1P 131583-51-2P 131583-52-3P
131583-53-4P 131583-57-8P 131583-58-9P 131583-60-3P 131583-61-4P
131583-63-6P 131583-64-7P 131583-65-8P 131583-66-9P 131583-67-0P
131583-71-6P 131583-72-7P 131583-74-9P 131583-75-0P 131583-76-1P
131583-77-2P 131583-79-4P 131583-81-8P 131583-83-0P 131583-84-1P
131583-87-4P 131583-88-5P 131583-89-6P 131583-90-9P 131583-91-0P
131583-92-1P 131583-93-2P 131583-95-4P 131583-96-5P 131583-97-6P
131583-98-7P 131583-99-8P 131584-01-5P 131584-02-6P 131584-03-7P
131584-04-8P 131584-05-9P 131584-07-1P 131584-09-3P 131584-11-7P
131584-12-8P 131584-13-9P 131584-14-0P 131584-15-1P 131584-16-2P
131584-17-3P 131584-18-4P 131584-19-5P 131584-20-8P 131584-21-9P
131584-22-0P 131584-23-1P 131584-24-2P 131584-25-3P 131584-26-4P
131584-27-5P 131584-28-6P 131584-29-7P 131584-30-0P 131584-33-3P
131584-36-6P 131584-37-7P 131584-38-8P 131584-40-2P 131584-41-3P
131584-42-4P 131584-43-5P 131584-44-6P 131584-45-7P 131584-46-8P
131584-47-9P 131584-48-0P 131584-49-1P 131584-50-4P 131584-51-5P
131584-52-6P 131584-53-7P 131584-54-8P 131584-55-9P 131584-56-0P
131584-57-1P 131584-58-2P 131584-59-3P 131584-60-6P 131584-61-7P
131584-62-8P 131584-63-9P 131584-64-0P 131584-65-1P 131584-66-2P
131584-67-3P 131584-68-4P 131584-69-5P 131584-70-8P 131584-71-9P
131584-73-1P 131584-74-2P 131584-76-4P 131584-77-5P 131584-78-6P
131584-79-7P 131584-80-0P 131584-81-1P 131584-82-2P 131584-83-3P
131584-85-5P 131584-87-7P 131584-88-8P 131584-89-9P 131584-90-2P
131584-92-4P 131584-93-5P 131584-94-6P 131584-95-7P 131584-98-0P
131584-99-1P 131585-00-7P 131585-01-8P 131585-02-9P 131585-03-0P
131585-04-1P 131585-05-2P 131585-06-3P 131585-07-4P 131585-08-5P
131585-09-6P 131585-10-9P 131585-11-0P 131585-12-1P 131585-13-2P
131585-14-3P 131585-15-4P 131585-16-5P 131585-17-6P 131585-18-7P
131585-19-8P 131585-22-3P 131585-23-4P 131585-24-5P 131585-25-6P
131585-26-7P 131585-27-8P 131585-28-9P 131585-29-0P 131585-30-3P
131585-31-4P 131585-32-5P 131585-33-6P 131585-34-7P 131585-35-8P
131585-36-9P 131585-37-0P 131585-39-2P 131585-42-7P 131585-47-2P
131585-48-3P 131585-49-4P 131585-50-7P 131585-51-8P 131585-52-9P
131585-53-0P 131585-54-1P 131585-55-2P 131585-56-3P 131585-57-4P
131585-58-5P 131585-59-6P 131585-60-9P 131585-61-0P 131585-62-1P
131585-63-2P 131585-64-3P 131585-65-4P 131585-66-5P 131585-67-6P

131585-68-7P 131585-69-8P 131585-70-1P 131585-71-2P 131585-72-3P
131585-73-4P 131585-74-5P 131585-75-6P 131585-76-7P 131585-77-8P
131585-78-9P 131585-79-0P 131585-80-3P 131585-81-4P 131585-82-5P
(carbostyril oxytocin receptor antagonists)

IT **131583-08-9P**
(carbostyril oxytocin receptor antagonists)

RN 131583-08-9 USPATFULL

CN Benzamide, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-N-methyl-N-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



L16 ANSWER 17 OF 27 USPATFULL on STN

AB There are provided a catalyst, a method for making this catalyst, and a process for using this catalyst in the alkylation of an isoparaffin with an olefin to provide an alkylate. The catalyst may be made from an as-synthesized material which, upon calcination, is capable of generating zeolites designated MCM-22. The as-synthesized material is then combined with a binder material, such as alumina, by an extrusion process. The uncalcined bound material may then be ammonium exchanged, followed by a calcination treatment. The as-synthesized material may also be swollen with a suitable swelling agent, such as a cetyltrimethylammonium compound, prior to the binding process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	94:88661 USPATFULL
TITLE:	Catalyst and process for isoparaffin-olefin alkylation
INVENTOR(S):	Chu, Cynthia T-W., Moorestown, NJ, United States Husain, Altaf, Marlton, NJ, United States Keville, Kathleen M., Beaumont, TX, United States Lissy, Daria N., Glen Mills, PA, United States
PATENT ASSIGNEE(S):	Mobil Oil Corporation, Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5354718		19941011
APPLICATION INFO.:	US 1993-42907		19930405 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Dees, Carl F.
LEGAL REPRESENTATIVE:	McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1,17
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . used in this extrusion process usually includes a substantial amount of chemically bound water in the form of hydroxyl groups **covalently** bonded to aluminum atoms.
SUMM . . . crush strength by a condensation reaction, whereby hydroxyl groups associated with aluminum atoms in the binder react to form Al-O-Al **linkages** and to liberate water.
IT 108-91-8, Aminocyclohexane, reactions 111-49-9 505-66-8, 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2, Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6** 116355-70-5
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)
IT **46244-96-6**
(directing agent; manuf. of catalyst for isoparaffin-olefin alkylation)
RN 46244-96-6 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN
AB The halide and hydroxide salts of the N,N,N-trimethyl-1-adamantylammonium ion have hydration behaviors which are different from the common patterns shown by all other quaternary ammonium ion halide and hydroxide salts we have studied. These differences include formation of higher iodide and bromide hydrates, failure to form halide monohydrates, and the existence of unusual mol. ions with three-center **covalent** hydrogen bonding in the lower fluoride and hydroxide hydrates. The 1H NMR spectrum of N,N,N-trimethyl-1-adamantylammonium ion is not consistent with that expected from application of conventional chem. shift rules. Comparison with the model compds. trimethyl-i-pentylammonium and tetra-i-pentylammonium ions, which have similar C-H arrangements but lack the tricyclic cage, demonstrate that through-cage interactions spread pos. charge over the whole structure of the N,N,N-trimethyl-1-adamantylammonium ion. The diffusely charged nature of the ion is correlated with the obsd. anomalous hydration behavior of its salts.
ACCESSION NUMBER: 1995:120168 HCAPLUS
DOCUMENT NUMBER: 122:9373
TITLE: Hydrogen bonding. Part 59. NMR study of N,N,N-trimethyl-1-adamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions; an explanation for the anomalous hydration behavior of N,N,N-trimethyl-1-adamantylammonium ion salts
AUTHOR(S): Harmon, Kenneth M.; Bulgarella, Jennifer A.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309, USA
SOURCE: Journal of Molecular Structure (1994), 326(1-3), 157-62
CODEN: JMOSB4; ISSN: 0022-2860
DOCUMENT TYPE: Journal
LANGUAGE: English

AB . . . of higher iodide and bromide hydrates, failure to form halide monohydrates, and the existence of unusual mol. ions with three-center **covalent** hydrogen bonding in the lower fluoride and hydroxide hydrates. The 1H NMR spectrum of N,N,N-trimethyl-1-adamantylammonium ion is not consistent with. . .

IT 37841-17-1P, Tetraisopentylammonium **46244-96-6P** 114328-82-4P 159389-92-1P, Trimethylisopentylammonium iodide
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(NMR of trimethyladamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions)

IT **3717-61-1**, 1-Adamantyltrimethylammonium iodide **53075-09-5**, N,N,N-Trimethyl-1-adamantylammonium hydroxide **128346-46-3** **138764-52-0** **151299-37-5**
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(anomalous hydration behavior of)

IT **46244-96-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(NMR of trimethyladamantylammonium, trimethyl-i-pentylammonium, and tetra-i-pentylammonium ions)

RN 46244-96-6 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



IT **3717-61-1**, 1-Adamantyltrimethylammonium iodide **53075-09-5**, N,N,N-Trimethyl-1-adamantylammonium hydroxide **128346-46-3** **138764-52-0** **151299-37-5**
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(anomalous hydration behavior of)

RN 3717-61-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



RN 53075-09-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide (9CI) (CA INDEX NAME)



● OH^-

RN 128346-46-3 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RN 138764-52-0 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 151299-37-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride (9CI) (CA INDEX NAME)



F^-

L16 ANSWER 19 OF 27 USPATFULL on STN

AB There is provided a crystalline oxide material with a characteristic X-ray diffraction pattern. This material may be a layered material, which is swollen or pillared. Upon calcination of the swollen material, the layers collapse and condense upon one another in a somewhat disordered fashion to form a non-swellable material. However, the swollen layered material may be intercalated with polymeric oxide pillars to maintain layer separation, even after calcination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	93:82594 USPATFULL
TITLE:	Crystalline oxide material
INVENTOR(S):	Kresge, Charles T., West Chester, PA, United States Roth, Wieslaw J., Sewell, NJ, United States Simmons, Kenneth G., Williamstown, NJ, United States Vartuli, James C., West Chester, PA, United States
PATENT ASSIGNEE(S):	Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5250277		19931005
APPLICATION INFO.:	US 1991-811360		19911220 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Breneman, R. Bruce
LEGAL REPRESENTATIVE:	McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-**linked** with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-**linking** agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross **linking** agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .

DETD . . . the layers collapse and condense upon one another. These collapsed and condensed layers are not swellable and are apparently chemically **linked** to one another by **covalent** bonds.

However, the layers of the collapsed and condensed swollen materials tend to be stacked upon one another in a. . .

IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8, 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2, Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6** 116355-70-5
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

IT **46244-96-6**
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

RN 46244-96-6 USPATFULL

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 27 USPATFULL on STN

AB There is provided a pillared, layered crystalline oxide material and a method for making this material. This material may be prepared by intercepting a swellable layered oxide before calcination. The intercepted material is swollen and pillared. If the material is not intercepted in this manner, it is transformed into a zeolite by calcination. The pillared material may have a large degree of catalytic activity, and it may have rather porous layers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	93:59111 USPATFULL
TITLE:	Crystalline oxide material
INVENTOR(S):	Kresge, Charles T., West Chester, PA, United States Roth, Wieslaw J., Sewell, NJ, United States Simmons, Kenneth G., Williamstown, NJ, United States Vartuli, James C., West Chester, NJ, United States
PATENT ASSIGNEE(S):	Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5229341		19930720
APPLICATION INFO.:	US 1991-811384		19911220 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-640329, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640339, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-640341, filed on 11 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-776718, filed on 15 Oct 1991, now abandoned which is a continuation of Ser. No. US 1991-640330, filed on 11 Jan 1991, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted

PRIMARY EXAMINER: Dees, Carl F.
LEGAL REPRESENTATIVE: McKillop, Alexander J., Santini, Dennis P., Kenehan, Jr., Edward F.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . layers of a layered material. For example, U.S. Pat. No. 4,216,188 incorporated herein by reference discloses a clay which is cross-**linked** with metal hydroxide prepared from a highly dilute colloidal solution containing fully separated unit layers and a cross-**linking** agent comprising a colloidal metal hydroxide solution. However, this method requires a highly dilute forming solution of clay (less than. . . to effect full layer separation prior to incorporation of the pillaring species, as well as positively charged species of cross **linking** agents. U.S. Pat. No. 4,248,739, incorporated herein by reference, relates to stable pillared interlayered clay prepared from smectite clays reacted. . .

IT 108-91-8, Aminocyclohexane, uses 111-49-9 505-66-8, 1,4-Diazacycloheptane 1003-03-8, Aminocyclopentane 1121-92-2, Azacyclooctane 5452-35-7, Aminocycloheptane **46244-96-6** 116355-70-5
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

IT **46244-96-6**
(directing agent, in prepn. of pillared layered oxide materials, as catalysts and sorbents)

RN 46244-96-6 USPATFULL
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB N,N,N-trimethyl-1-adamantylammonium hydroxide tetrahydrate, dihydrate, monohydrate, and hemihydrate are stable cryst. materials. IR comparison with tetramethylammonium hydroxide tetrahydrate of known structure suggests that the tetrahydrate is a framework clathrate species in which hydroxide ions act as hydrogen bond donors. The dihydrate appears to contain both stronger and weaker hydrogen-bonded water mols., unlike tetramethylammonium hydroxide dihydrate in which all water mols. are similar. The IR spectrum of the monohydrate is of a significantly different type, and supports the presence of HOHOH- mol. ions contg. **covalent** three-center OHO hydrogen bonds. A structure is proposed for the water-hydroxide ion arrangement in the monohydrate in which such HOHOH- ions are **linked** into a sheet through hydrogen bonds from terminal OH groups. The hemihydrate also appears to contain the HOHOH- species found in the monohydrate, and thus would also contain an equal no. of OH- ions. A structure is proposed for the hemihydrate in which alternate chains of the sheet structure of the monohydrate are dehydrated and the remaining chains are **linked** through OH- ions which act

as both hydrogen bond donors and acceptors.

ACCESSION NUMBER: 1993:569434 HCAPLUS
DOCUMENT NUMBER: 119:169434
TITLE: Hydrogen bonding. Part 47. Stoichiometry, stability, and IR spectra of N,N,N-trimethyl-1-adamantylammonium hydroxide hydrates; IR evidence for a **covalent** HOHOH- species in the monohydrate and hemihydrate
AUTHOR(S): Harmon, Kenneth M.; Southworth, Barbara A.; Mounts, Peggy A.
CORPORATE SOURCE: Department of Chemistry, Oakland University, Rochester, MI, 48309, USA
SOURCE: Journal of Molecular Structure (1993), 296(1-2), 69-78
CODEN: JMOSB4; ISSN: 0022-2860
DOCUMENT TYPE: Journal
LANGUAGE: English

TI Hydrogen bonding. Part 47. Stoichiometry, stability, and IR spectra of N,N,N-trimethyl-1-adamantylammonium hydroxide hydrates; IR evidence for a **covalent** HOHOH- species in the monohydrate and hemihydrate

AB . . . IR spectrum of the monohydrate is of a significantly different type, and supports the presence of HOHOH- mol. ions contg. **covalent** three-center OHO hydrogen bonds. A structure is proposed for the water-hydroxide ion arrangement in the monohydrate in which such HOHOH- ions are **linked** into a sheet through hydrogen bonds from terminal OH groups. The hemihydrate also appears to contain the HOHOH- species found. . . the hemihydrate in which alternate chains of the sheet structure of the monohydrate are dehydrated and the remaining chains are **linked** through OH- ions which act as both hydrogen bond donors and acceptors.

IT **150115-20-1P 150115-21-2P 150115-22-3P 150115-23-4P**
RL: PREP (Preparation)
(prepn. and IR spectroscopic properties of)

IT **150115-20-1P 150115-21-2P 150115-22-3P 150115-23-4P**
RL: PREP (Preparation)
(prepn. and IR spectroscopic properties of)

RN 150115-20-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, tetrahydrate (9CI) (CA INDEX NAME)



O OH-

O4 H2O

RN 150115-21-2 HCAPLUS

Delacroix

CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, dihydrate (9CI) (CA INDEX NAME)



● OH^-

●2 H_2O

RN 150115-22-3 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, monohydrate (9CI) (CA INDEX NAME)



● OH^-

● H_2O

RN 150115-23-4 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide, hydrate (2:1) (9CI) (CA INDEX NAME)



⊛ OH⁻

⊛1/2 H_2O

L16 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB N,N,N-Trimethyl-1-adamantylammonium fluoride forms two cryst. hydrates, a trihydrate and a hemihydrate. The IR spectrum of the trihydrate demonstrates the presence of H2O bound by strong electrostatic hydrogen bonds in a framework clathrate structure. The trihydrate can be recrystd. from acetone to yield crystals which should be suitable for diffraction studies. The IR spectrum of bound H2O in the hemihydrate is unlike that of H2O in any tetraalkylammonium salt hydrate that has been previously examd. This spectrum resembles that of the H2F3- ion in N,N,N-trimethyl-1-adamantylammonium dihydrogen trifluoride, and a model for the hemihydrate is proposed in which a bridging H2O mol. is bound to two F- ions by unsym. **covalent**, three-center hydrogen bonds. An ab initio calcn. supports the proposed structure.

ACCESSION NUMBER: 1992:83090 HCAPLUS
DOCUMENT NUMBER: 116:83090
TITLE: Hydrogen bonding. Part 37. N,N,N-trimethyl-1-adamantylammonium fluoride trihydrate and hemihydrate; evidence for **covalent** hydrogen bonding in the hemihydrate
AUTHOR(S): Harmon, Kenneth M.; Mounts, Peggy A.; Wilson, Karen E.
CORPORATE SOURCE: Dep. Chem., Oakland Univ., Rochester, MI, 48309, USA
SOURCE: Journal of Molecular Structure (1991), 249(2-4), 161-72
CODEN: JMOSB4; ISSN: 0022-2860
DOCUMENT TYPE: Journal
LANGUAGE: English

TI Hydrogen bonding. Part 37. N,N,N-trimethyl-1-adamantylammonium fluoride trihydrate and hemihydrate; evidence for **covalent** hydrogen bonding in the hemihydrate

AB . . . model for the hemihydrate is proposed in which a bridging H2O mol. is bound to two F- ions by unsym. **covalent**, three-center hydrogen bonds. An ab initio calcn. supports the proposed structure.

IT **138863-18-0 138863-19-1**
RL: PRP (Properties)
(IR and hydrogen bonding in)

IT **138863-18-0 138863-19-1**
RL: PRP (Properties)
(IR and hydrogen bonding in)

RN 138863-18-0 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride, trihydrate (9CI) (CA INDEX NAME)



● F^-

● 3 H_2O

RN 138863-19-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, fluoride, hydrate (2:2:1) (9CI) (CA INDEX NAME)



● F^-

1/2 H_2O

L16 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
GI



I

AB Mol. sieves, particularly zeolites, are prepd. using adamantane compds.

Delacroix

(I) [Z = CH2 or **covalent** bond; R1 = OH, N(X1X2), where independently X1, X2 = H, lower alkyl, or a moiety of the formula N+(Y1Y2Y3)A-, wherein independently Y1, Y2, Y3 = lower alkyl and A- = anion that is not detrimental to the formation of the mol. sieve; R2 = H, lower alkyl; independently R3, R4 = H, OH, N(X1X2), or the moiety N+(Y1Y2Y3)A- defined above] as templates. These mol. sieves are uniform in size and allow selective sepn. of hydrocarbons. Thus, 10 g 1-adamantamine was dissolved in 60 mL DMF, 29 g Bu3N was added, and 28.4 g MeI was added dropwise while the reaction was stirred in an ice bath. The next day, crystals of N,N,N-trimethyl-1 adamantammonium iodide (II) had formed. A 1st soln. was prepd. by adding 5 g Na silicate (Na2O 0.45, SiO2 1.46, H2O 3.10 g), 6 mL H2O, and 1.56 g II. A 2nd soln. was prepd. using 0.24 g Al2(SO4)3.16H2O and 0.67 g 50 wt.% NaOH in 6 mL H2O, and added to the 1st soln. under agitation to obtain a milky soln. The reactor was closed and heated at 140.degree. for 6 days. The resulting solids were washed 5 times with deionized H2O, followed by once each with MeOH and Me2CO, and were shown to correspond to zeolite SSZ-13.

ACCESSION NUMBER: 1987:499231 HCAPLUS
DOCUMENT NUMBER: 107:99231
TITLE: Process for preparing molecular sieves using adamantane template
INVENTOR(S): Zones, Stacey I.
PATENT ASSIGNEE(S): Chevron Research Co., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4665110	A	19870512	US 1986-823700	19860129

PRIORITY APPLN. INFO.: US 1986-823700 19860129

AB Mol. sieves, particularly zeolites, are prepd. using adamantane compds. (I) [Z = CH2 or **covalent** bond; R1 = OH, N(X1X2), where independently X1, X2 = H, lower alkyl, or a moiety of the formula N+(Y1Y2Y3)A-,. . .

IT 700-57-2 768-94-5 768-95-6 **3717-61-1**, N,N,N-Trimethyl-1-adamantammonium iodide 39234-35-0 40505-99-5, N,N,N-Trimethyl-2-adamantammonium iodide **53075-09-5** 53075-10-8 109954-44-1
RL: USES (Uses)
(template, in SSZ-type zeolite manuf.)

IT **3717-61-1**, N,N,N-Trimethyl-1-adamantammonium iodide
53075-09-5
RL: USES (Uses)
(template, in SSZ-type zeolite manuf.)

RN 3717-61-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



I^-

RN 53075-09-5 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-aminium, N,N,N-trimethyl-, hydroxide (9CI) (CA INDEX NAME)



OH^-

L16 ANSWER 24 OF 27 USPATFULL on STN
AB **Conjugated** ketone compounds of the formula: ##STR1## wherein Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or more substituents selected from the group consisting of chlorine, bromine, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, trifluoromethyl and methylenedioxy, R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.7 -C.sub.8 aralkyl or adamantyl, R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl or C.sub.3 -C.sub.6 cycloalkyl, or when R.sub.1 and R.sub.2 are taken together with the nitrogen atom to which they are attached, they form a heterocyclic amino group containing up to 8 carbon atoms, A is straight or branched C.sub.1 -C.sub.3 alkylene, N-[4-(p-chlorophenyl)-4-oxo-2-trans-butenyl]morpholine and N-[4-(p-methoxyphenyl)-4-oxo-2-trans-butenyl]piperidine being excluded, and their non-toxic salts, which are useful as blood platelet anti-aggregative agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 83:56156 USPATFULL
TITLE: **Conjugated** ketone compounds in preventing platelet thrombosis
INVENTOR(S): Kojima, Atsuyuki, Hyogo, Japan
Irie, Tsunemasa, Hyogo, Japan
Harada, Shuichi, Osaka, Japan
Kameno, Yoshito, Osaka, Japan
Katsube, Junki, Osaka, Japan
Yamamoto, Hisao, Hyogo, Japan
PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4418079		19831129
APPLICATION INFO.:	US 1981-335522		19811229 (6)

RELATED APPLN. INFO.: Division of Ser. No. US 1980-217043, filed on 16 Dec 1980, now abandoned which is a continuation of Ser. No. US 1978-973639, filed on 27 Dec 1978, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-2938	19780113
	JP 1978-2939	19780113

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI **Conjugated** ketone compounds in preventing platelet thrombosis

AB **Conjugated** ketone compounds of the formula: ##STR1## wherein Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or more substituents. . .

SUMM The present invention relates to **conjugated** ketone compounds, and their production and use.

SUMM The objective **conjugated** ketone compounds are representable by the formula: ##STR2## wherein Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or. . .

SUMM The **conjugated** ketone compounds [I] can form acid addition salts (e.g. hydrochlorides, hydrobromides, sulfates, oxalates, citrates, fumarates, maleates, tartrates, etc.), and these. . .

SUMM The **conjugated** ketone compounds [I] and their non-toxic salts inhibit aggregation of blood platelets and are useful for prevention of intravascular thrombosis,. . .

SUMM Among the **conjugated** ketone compounds [I], those of the following formula are preferred: ##STR3## wherein Ar' is naphthyl, furyl, thienyl or phenyl optionally. . .

SUMM The **conjugated** ketone compounds [I] and their non-toxic salts can be administered to warm-blooded animals either alone or in combination with pharmaceutically. . .

SUMM The **conjugated** ketone compounds [I] can be prepared as shown in the following scheme: ##STR6## wherein Ar, R.sub.1, R.sub.2 and A are. . .

SUMM Pharmacological evaluation has indicated the **conjugated** ketone compounds [I] of the invention show an anti-aggregative activity for blood platelets.

SUMM The **conjugated** ketone compounds [I] were also tested ex vivo in rats where ADP or collagen was used to induce aggregation in. . .

SUMM The **conjugated** ketone compounds [I] are superior blood platelet anti-aggregative agents to the **conjugated** ketone derivatives as disclosed in U.S. Pat. No. 4,012,515 in many respects. The compounds as disclosed in that patent are. . .

IT 71678-41-6P 71678-42-7P 71678-43-8P 71678-44-9P 71678-45-0P
71678-46-1P 71678-47-2P 71678-48-3P 71678-49-4P 71678-50-7P
71678-51-8P 71678-52-9P 71678-53-0P 71678-54-1P 71678-55-2P
71678-57-4P 71678-58-5P 71678-59-6P 71678-60-9P 71678-61-0P
71678-62-1P 71678-63-2P 71678-64-3P 71678-65-4P 71678-66-5P

71678-67-6P 71678-68-7P 71678-69-8P 71679-44-2P 71679-45-3P
71679-46-4P 71679-47-5P 71679-48-6P 71679-49-7P 71679-50-0P
71679-51-1P **71679-52-2P** 71679-53-3P 71679-54-4P
71679-55-5P 71679-56-6P 71679-57-7P 71679-58-8P 71679-59-9P
71679-60-2P 71679-61-3P 71895-92-6P 71895-93-7P 71895-97-1P
(prepn. and blood platelet aggregation inhibitory activity of)

IT **71679-52-2P**
(prepn. and blood platelet aggregation inhibitory activity of)

RN 71679-52-2 USPATFULL

CN 2-Buten-1-one, 4-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-1-phenyl-, hydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

L16 ANSWER 25 OF 27 USPATFULL on STN

AB Compounds of the formula ##STR1## wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula ##STR2## R.sup.1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl;

R.sup.2 is --H or lower aliphatic hydrocarbyl;

R.sup.3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R.sup.4, alkylene;

R.sup.4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R.sup.3, alkylene;

or R.sup.2,R.sup.3 and R.sup.4, together with the carbon to which each is bound, are adamantyl; and

n is 3, 4 or 5;

and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are

discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	81:985 USPATFULL
TITLE:	Acylhydrocarbylaminoalkanoic acids, compositions and uses
INVENTOR(S):	Krastinat, Walter, Constance, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4243678		19810106
APPLICATION INFO.:	US 1978-969701		19781215 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	LU 1977-78865	19771230
	CH 1978-6504	19780614
	CH 1978-6505	19780614

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Reamer, James H.
LEGAL REPRESENTATIVE:	Berman, Aisenberg & Platt
NUMBER OF CLAIMS:	100
EXEMPLARY CLAIM:	1,51
LINE COUNT:	3768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . unsaturation is either mono (as in allyl) or multiple (as in butadienyl), and multiple unsaturation can (but need not) be **conjugated**; includes straight-chain or branched alkyl radicals with, e.g., from 1 to 7 carbon atoms; straight-chain alkyl is, e.g., methyl, ethyl,. . .

IT 4521-61-3P 4789-08-6P 60737-65-7P 71454-82-5P 71454-87-0P
71454-88-1P 71454-91-6P 71454-93-8P 71454-95-0P 71454-96-1P
71454-98-3P 71454-99-4P 71455-00-0P 71455-01-1P 71455-02-2P
71455-03-3P **71455-04-4P** 71455-06-6P 71455-07-7P
71455-11-3P 71455-13-5P 71455-14-6P 71455-15-7P 71455-17-9P
71455-30-6P 71455-31-7P 71455-32-8P 71455-33-9P 71455-34-0P
71455-36-2P 71455-37-3P 71455-38-4P 71455-39-5P 71455-40-8P
71455-41-9P 71455-42-0P **71455-43-1P** 71455-44-2P
71455-45-3P 71455-46-4P 71455-47-5P 71455-48-6P 71455-50-0P
71455-51-1P 71455-52-2P 71455-53-3P 71455-54-4P 71455-55-5P
71455-56-6P 71455-57-7P 71455-58-8P 71455-59-9P 71455-60-2P
71455-61-3P 71455-62-4P 71455-63-5P 71455-64-6P 71510-64-0P
71510-65-1P 71510-66-2P 71510-67-3P 71510-68-4P 71510-69-5P
71510-70-8P 71563-92-3P 71564-71-1P 74296-84-7P 74296-85-8P
74296-86-9P 74296-88-1P 74296-90-5P 74296-91-6P 74296-93-8P
74296-95-0P 74296-96-1P 74296-97-2P 74296-98-3P 74296-99-4P
74297-01-1P 74297-02-2P 74297-03-3P 74297-04-4P 74297-05-5P
74297-06-6P 74297-07-7P 74297-09-9P 74297-10-2P 74297-12-4P
74297-13-5P 74297-14-6P 74297-15-7P 74297-16-8P 74297-17-9P
74297-18-0P 74297-19-1P 74297-20-4P 74297-21-5P 74297-23-7P
74297-24-8P 74297-25-9P 74297-26-0P 74297-27-1P 74297-28-2P
74297-29-3P 74297-30-6P 74297-31-7P 74297-32-8P 74297-33-9P
74297-34-0P 74297-38-4P 74297-39-5P 74297-41-9P 74297-45-3P
74304-86-2P 78331-41-6P 78331-42-7P 78331-43-8P 78331-44-9P

78331-45-0P 78331-46-1P 78331-47-2P
(prepn. of)
IT **71455-04-4P 71455-43-1P**
(prepn. of)
RN 71455-04-4 USPATFULL
CN Butanoic acid, 4-[(4-chlorobenzoyl)tricyclo[3.3.1.13,7]dec-1-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 71455-43-1 USPATFULL
CN Butanoic acid, 4-[(4-chlorobenzoyl)tricyclo[3.3.1.13,7]dec-1-ylamino]- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN
AB Fifty title compds. trans-RCOCH:CHZNR1R2 (I; R = naphthyl, furyl, thienyl, Ph optionally substituted by .gtoreq.1 of Cl, Br, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, CF3, methylenedioxy; Z = C1-3 alkylene; R1 = C1-6 alkyl, C3-5 alkenyl, C3-6 cycloalkyl, C7-8 aralkyl, adamantyl; R2 = C1-6 alkyl, C3-5 alkenyl, C3-6 cycloalkyl; NR1R2 = heterocyclic amino contg. .gtoreq.8 C atoms) and their acid addn. salts were prepd. Thus, I.HBr (R = Ph, Z = CH2, R1 = R2 = Et) was prepd. from Et2NH by sequential treatment with HC.tplbond.CCH2Br, EtMgBr, PhCHO, LiAlH4, MnO2, and HBr. The blood platelet antiaggregative activities of I were assessed in rats and in vitro. Compared with the known butyrophenone neuroleptics, I show increased antiaggregative activity with smaller or no neuroleptic properties.

ACCESSION NUMBER:	1980:426110 HCAPLUS
DOCUMENT NUMBER:	93:26110
TITLE:	**Conjugated** ketones useful as blood platelet antiaggregative agents
INVENTOR(S):	Kojima, Atsuyuki; Irie, Tsunemasa; Harada, Shuichi; Kameno, Yoshito; Katsube, Junki; Yamamoto, Hisao
PATENT ASSIGNEE(S):	Sumitomo Chemical Co., Ltd., Japan
SOURCE:	Brit. UK Pat. Appl., 13 pp. CODEN: BAXXDU
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2012749	A1	19790801	GB 1979-1123	19790111
GB 2012749	B2	19821222		
JP 54098755	A2	19790803	JP 1978-2938	19780113
JP 54098733	A2	19790803	JP 1978-2939	19780113
JP 61025020	B4	19860613		
CA 1151164	A1	19830802	CA 1979-319260	19790108
DK 7900127	A	19790714	DK 1979-12779	19790111
FR 2414495	A1	19790810	FR 1979-667	19790111
BE 873429	A1	19790712	BE 1979-192855	19790112
SE 7900290	A	19790714	SE 1979-290	19790112
AU 7943337	A1	19790719	AU 1979-43337	19790112
AU 523214	B2	19820715		
ES 476818	A1	19791201	ES 1979-476818	19790112
AT 7900232	A	19810115	AT 1979-232	19790112
AT 363461	B	19810810		
HU 19750	O	19810428	HU 1979-SU1004	19790112
HU 177514	P	19811028		
CH 640213	A	19831230	CH 1979-313	19790112
NL 7900307	A	19790717	NL 1979-307	19790115
US 4418079	A	19831129	US 1981-335522	19811229
PRIORITY APPLN. INFO.:			JP 1978-2938	19780113
			JP 1978-2939	19780113
			US 1978-973639	19781227
			US 1980-217043	19801216

TI **Conjugated** ketones useful as blood platelet antiaggregative agents

IT 71678-41-6P 71678-42-7P 71678-43-8P 71678-44-9P 71678-45-0P
71678-46-1P 71678-47-2P 71678-48-3P 71678-49-4P 71678-50-7P
71678-51-8P 71678-52-9P 71678-53-0P 71678-54-1P 71678-55-2P
71678-57-4P 71678-58-5P 71678-59-6P 71678-60-9P 71678-61-0P
71678-62-1P 71678-63-2P 71678-64-3P 71678-65-4P 71678-66-5P
71678-67-6P 71678-68-7P 71678-69-8P 71679-44-2P 71679-45-3P
71679-46-4P 71679-47-5P 71679-48-6P 71679-49-7P 71679-50-0P
71679-51-1P **71679-52-2P** 71679-53-3P 71679-54-4P
71679-55-5P 71679-56-6P 71679-57-7P 71679-58-8P 71679-59-9P
71679-60-2P 71679-61-3P 71895-92-6P 71895-93-7P 71895-97-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and blood platelet aggregation inhibitory activity of)

IT **71679-52-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and blood platelet aggregation inhibitory activity of)

RN 71679-52-2 HCAPLUS

CN 2-Buten-1-one, 4-(methyltricyclo[3.3.1.13,7]dec-1-ylamino)-1-phenyl-, hydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



O HCl

L16 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2003 ACS on STN

AB Aliphatic primary amines react with 1-bromoadamantane (I) only at 170-80.degree. (sealed tube reaction). Aliphatic secondary amines require 200-10.degree. to react with I. Also prepd. was 1,1' -diadamantylamine. The aromatic amines react with I in 2 ways. Thus PhNH2 gave .apprx.20% N-(adamant-1-yl)aniline (II) and .apprx.7% 4-(adamant-1-yl)aniline. Similarly, o-MeC6H4NH2 reacted with I to give 26.2% 2-methyl-4-(adamant-1-yl)aniline and 4.1% 2-methyl-N-(adamant-1-yl)aniline. However, m-MeC6H4NH2 or p-MeC6H4-NH2 gave only 3-methyl-N-(adamant-1-yl)aniline (III) or 4-methyl-N-(adamant-1-yl)aniline, resp. PhNMe2 also gave only 1 product: 4-(adamant-1-yl)dimethylaniline. The methylation of II or III gave, resp., N-methyl-N-(adamant-1-yl)-aniline and 3-methyl-N-methyl-N-(adamant-1-yl)aniline. The tertiary amines, due to the steric hindrance, are not **conjugated** through the central N atom.

ACCESSION NUMBER: 1969:412643 HCAPLUS
DOCUMENT NUMBER: 71:12643
TITLE: Adamantane and its derivatives. XVIII. Reaction of 1-bromoadamantane with amines
AUTHOR(S): Stepanov, F. N.; Stolyarov, Z. E.
CORPORATE SOURCE: Kiev. Politekh. Inst., Kiev, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1969), 5(3), 537-41
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB . . . methylation of II or III gave, resp., N-methyl-N-(adamant-1-yl)-aniline and 3-methyl-N-methyl-N-(adamant-1-yl)aniline. The tertiary amines, due to the steric hindrance, are not **conjugated** through the central N atom.

IT 99-97-8P 121-69-7P 281-23-2P 609-72-3P 3717-50-8P 3717-60-0P **3788-37-2P** 7123-77-5P 19984-34-0P 19984-37-3P 19984-39-5P 19984-51-1P 22947-32-6P 22947-33-7P 22947-34-8P 22947-36-0P 22947-39-3P 22947-40-6P 22947-41-7P 22947-42-8P 22947-46-2P 22947-47-3P 22947-50-8P 22947-51-9P 22947-52-0P 22947-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT **3788-37-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 3788-37-2 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N,N-diethyl- (9CI) (CA INDEX NAME)

10/016850



=> file stnguide

Delacroix